WO2010001257A2 - Novel solid state forms of laquinimod and its sodium salt - Google Patents
Novel solid state forms of laquinimod and its sodium salt Download PDFInfo
- Publication number
- WO2010001257A2 WO2010001257A2 PCT/IB2009/006560 IB2009006560W WO2010001257A2 WO 2010001257 A2 WO2010001257 A2 WO 2010001257A2 IB 2009006560 W IB2009006560 W IB 2009006560W WO 2010001257 A2 WO2010001257 A2 WO 2010001257A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- laquinimod
- solution
- crystalline form
- laquinimod sodium
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title claims abstract description 319
- 229960004577 laquinimod Drugs 0.000 title claims abstract description 318
- 239000007787 solid Substances 0.000 title claims description 33
- 159000000000 sodium salts Chemical class 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 145
- 230000008569 process Effects 0.000 claims abstract description 122
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 44
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 239000002904 solvent Substances 0.000 claims description 139
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 101
- 239000000203 mixture Substances 0.000 claims description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 60
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 57
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 53
- 239000000725 suspension Substances 0.000 claims description 52
- 238000001914 filtration Methods 0.000 claims description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 49
- 238000002329 infrared spectrum Methods 0.000 claims description 33
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 25
- 230000001476 alcoholic effect Effects 0.000 claims description 23
- 238000010992 reflux Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 238000010521 absorption reaction Methods 0.000 claims description 17
- 150000002576 ketones Chemical class 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 16
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 claims description 16
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 239000012296 anti-solvent Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- 229910002027 silica gel Inorganic materials 0.000 claims description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 12
- 230000008020 evaporation Effects 0.000 claims description 12
- 238000010899 nucleation Methods 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 10
- 238000010908 decantation Methods 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000004215 Carbon black (E152) Substances 0.000 claims description 5
- 150000008282 halocarbons Chemical class 0.000 claims description 5
- 229930195733 hydrocarbon Natural products 0.000 claims description 5
- 150000002430 hydrocarbons Chemical class 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 239000010409 thin film Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- 239000007822 coupling agent Substances 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 claims description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000023516 stroke disease Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- 229940011051 isopropyl acetate Drugs 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001144 powder X-ray diffraction data Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 2
- 229940100692 oral suspension Drugs 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 83
- 150000001875 compounds Chemical class 0.000 description 18
- -1 N-ethyl-N-phenylcarbamoyl acetic acid ethyl ester Chemical compound 0.000 description 17
- 239000000463 material Substances 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000005456 alcohol based solvent Substances 0.000 description 12
- 238000000113 differential scanning calorimetry Methods 0.000 description 11
- 238000002441 X-ray diffraction Methods 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000001757 thermogravimetry curve Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229920001684 low density polyethylene Polymers 0.000 description 4
- 239000004702 low-density polyethylene Substances 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000003759 ester based solvent Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004210 ether based solvent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 239000005453 ketone based solvent Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MYQFJMYJVJRSGP-UHFFFAOYSA-N 6-chloro-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C2=CC(Cl)=CC=C21 MYQFJMYJVJRSGP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000010431 corundum Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ASWXNYNXAOQCCD-UHFFFAOYSA-N dichloro(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Cl)(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 ASWXNYNXAOQCCD-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- PAIDZDPOJWEZLX-UHFFFAOYSA-N methyl 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OC)=C(O)C2=C1Cl PAIDZDPOJWEZLX-UHFFFAOYSA-N 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical class C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present disclosure relates to a novel crystalline form of laquinimod, process for the preparation, pharmaceutical compositions, and method of treating thereof.
- the present disclosure further relates to novel solid state forms of laquinimod sodium, process for the preparation, pharmaceutical compositions, and method of treating thereof.
- U.S. Patent No. 6,077,851 discloses a variety of quinoline-3-carboxamide derivatives and their salts, processes for their preparation, pharmaceutical compositions comprising the derivatives, and method of use thereof. These compounds are useful for clinical treatment of diseases resulting from autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis and, furthermore, diseases where pathologic inflammation plays a major role, such as asthma, atherosclerosis, stroke and Alzheimer's disease.
- diseases resulting from autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis
- diseases where pathologic inflammation plays a major role such as asthma, atherosclerosis, stroke and Alzheimer's disease.
- Laquinimod N-ethyl-N- phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide is important, since it is well-known as a pharmaceutically active substance under the name of Laquinimod.
- Laquinimod is a promising immunomodulatory agent and useful for the treatment of multiple sclerosis and its manifestations.
- Laquinimod is represented by the following structural formula:
- U.S. Patent No. 6,077,851 (hereinafter referred to as the '851 patent) describes several synthetic routes for preparing laquinimod.
- laquinimod is prepared by the reaction of l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3- carboxylic acid ethyl ester with N-ethylaniline in a suitable solvent such as toluene, xylene and the like, to produce a reaction mass containing laquinimod, followed by distillation of ethanol formed during the reaction and then subjected to usual work up to produce laquinimod, which is then converted into its sodium salt.
- a suitable solvent such as toluene, xylene and the like
- laquinimod is prepared by the reaction of 5-chloro isatoic anhydride with N-ethyl-N-phenylcarbamoyl acetic acid ethyl ester in the presence of methyl iodide and a strong base such as sodium hydride in a suitable solvent such as N,N-dimethylacetamide.
- laquinimod is prepared by the reaction of l,2-dihydro-4 ⁇ hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3- carboxylic acid with N-ethylaniline using coupling reagents such as carbodiimides and thionyl chloride in the presence of triethylamine to produce laquinimod.
- Laquinimod obtained by the processes described in the '851 patent is further recrystallized from methanol to produce laquinimod with greater than 95% purity.
- the product is obtained by suspending laquinimod in ethanol, adding 5M sodium hydroxide solution to the suspension by adjusting the pH to 8-12, stirring the reaction mixture for 30 minutes at ambient temperature and recovering the precipitated laquinimod sodium.
- U.S. Patent No. 6,875,869 (hereinafter referred to as the '869 patent) describes an improved process for the preparation of laquinimod comprising reacting 1 ,2-dihydro-4- hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3-carboxylic acid methyl ester with N- ethylaniline in the presence of a solvent selected from straight or branched alkanes and cycloalkanes or mixtures thereof with a boiling point between 80°C and 200°C, specifically n-heptane, n-octane or mixtures thereof.
- a solvent selected from straight or branched alkanes and cycloalkanes or mixtures thereof with a boiling point between 80°C and 200°C, specifically n-heptane, n-octane or mixtures thereof.
- PCT Publication No. WO 2007/047863 discloses a process for recrystallization of laquinimod sodium comprising dissolving laquinimod sodium in water to form an aqueous solution, concentrating the solution to form a concentrated solution, adding a water-miscible anti-solvent to the concentrated solution to form laquinimod sodium crystals, and isolating the laquinimod sodium crystals.
- Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and /or conformations of the molecule in the crystal lattice. Thus, in the strict sense, polymorphs are different crystalline forms of the same pure substance in which the molecules have different arrangements and / or configurations of the molecules".
- Polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph. It is therefore important to investigate all solid forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and infrared spectrometry (IR). Solvent medium and mode of isolation play very important role in obtaining one polymorphic form over another.
- XRD X-ray diffraction
- DSC Differential Scanning Calorimetry
- IR infrared spectrometry
- laquinimod crystalline Form A characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 7.15, 12.58, 14.84, 25.09 and 26.38 ⁇ 0.2 degrees.
- laquinimod sodium crystalline Form Al a novel and stable crystalline form of laquinimod sodium, designated as laquinimod sodium crystalline Form Al, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 9.1, 10.7 and 11.2 ⁇ 0.2 degrees.
- encompassed herein is a process for preparing the substantially pure and stable crystalline Form Al of laquinimod sodium.
- the novel crystalline Form Al of laquinimod sodium is consistently reproducible, does not have the tendency to convert to other forms and found to be more stable even after being stored at a temperature of about 40°C at a relative humidity of about 75% for at least about 1 month, specifically for a period of 3 months, or at a temperature of about 25 0 C at a relative humidity of about 60% for at least about 6 months.
- the crystalline Form Al of laquinimod sodium has a tapped density of about 0.4 g/ml to about 0.5 g/ml, is less electrostatic, and has good flow properties which is particularly suitable for bulk preparation and handling.
- the laquinimod sodium crystalline Form Al exhibits properties making it suitable for formulating laquinimod sodium.
- a novel process for preparing substantially pure crystalline Form A2 of laquinimod sodium is a novel process for preparing substantially pure crystalline Form A
- laquinimod sodium crystalline Form A3 a novel and stable crystalline form of laquinimod sodium, designated as laquinimod sodium crystalline Form A3, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 6.44, 6.65, 7.72 and 8.77 ⁇ 0.2 degrees.
- laquinimod sodium crystalline Form A4 a novel and stable crystalline form of laquinimod sodium, designated as laquinimod sodium crystalline Form A4, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 6.09, 7.46 and 10.42 ⁇ 0.2 degrees.
- encompassed herein is a process for preparing the substantially pure and stable crystalline Form A4 of laquinimod sodium.
- a novel and stable amorphous form of laquinimod sodium and use thereof for the preparation of laquinimod sodium is provided herein.
- composition comprising laquinimod crystalline Form A disclosed herein and one or more pharmaceutically acceptable excipients.
- a process for preparing a pharmaceutical formulation comprising combining laquinimod crystalline Form A with one or more pharmaceutically acceptable excipients.
- a pharmaceutical composition comprising a therapeutically effective amount of any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, and one or more pharmaceutically acceptable excipients.
- composition comprising any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium prepared according to processes disclosed herein and one or more pharmaceutically acceptable excipients.
- a process for preparing a pharmaceutical formulation comprising combining any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium prepared according to processes disclosed herein, with one or more pharmaceutically acceptable excipients.
- a method for treating a patient suffering from diseases caused by autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis and, furthermore, diseases where pathologic inflammation plays a major role, such as asthma, atherosclerosis, stroke and Alzheimer's disease; comprising administering any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, or a pharmaceutical composition that comprises any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein along with pharmaceutically acceptable excipients.
- diseases caused by autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis and, furthermore, diseases where pathologic inflammation plays
- each one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein for use in the pharmaceutical compositions has a 90 volume-percent of the particles (D 90 ) of less than or equal to about 500 microns, specifically less than or equal to about 300 microns, more specifically less than or equal to about 200 microns, still more specifically less than or equal to about 100 microns, and most specifically less than or equal to about 15 microns.
- Figure l is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod crystalline
- Figure 2 is a characteristic infra red (IR) spectrum of laquinimod crystalline Form A.
- Figure 3 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod crystalline Form A.
- Figure 4 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form Al .
- Figure 5 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
- Figure 6 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form Al .
- Figure 7 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form A2.
- Figure 8 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
- Figure 9 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form A2.
- Figure 10 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form A3.
- Figure 11 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
- Figure 12 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form A3.
- Figure 13 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form A4.
- Figure 14 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
- Figure 15 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form A4.
- Figure 16 is a characteristic powder X-ray diffraction (XRD) pattern of amorphous laquinimod sodium.
- Figure 17 is a characteristic infra red (IR) spectrum of amorphous laquinimod sodium.
- laquinimod crystalline Form A characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 1 ; ii) a powder X-ray diffraction pattern having peaks at about 7.15, 12.58, 14.84, 25.09 and 26.38 ⁇ 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 6.19, 8.78, 14.04, 14.37, 15.36, 16.20, 18.48, 18.81, 20.44, 20.73, 21.71, 23.21, 23.50, 23.76, 28.96 and 31.08 ⁇ 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 2; v) an IR spectrum having absorption bands at about 3081, 2976, 1647,
- a process for the preparation of a crystalline Form A of laquinimod comprising: a) providing a suspension of N-ethyl-N-phenyl- 1 ,2-dihydro-4-hydroxy-5-chloro- 1 -methyl-2- oxoquinoline-3-carboxamide (laquinimod or laquinimod acid) in a solvent medium comprising an ester solvent and a chlorinated hydrocarbon solvent; b) optionally, cooling the suspension obtained in step-(a); and c) recovering crystalline Form A of laquinimod from the suspension.
- the process can produce crystalline Form A of laquinimod in substantially pure form.
- substantially pure laquinimod crystalline Form A refers to the laquinimod crystalline Form A having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.3% and still more specifically greater than about 99.5% (measured by HPLC).
- the laquinimod crystalline Form A is stable, consistently reproducible, and is particularly suitable for bulk preparation and handling. Moreover, the crystalline Form A of laquinimod is useful intermediate in the preparation of laquinimod sodium in high purity.
- the crystalline Form A of laquinimod has good flow properties and stable at room temperature, enhanced temperature, at relative high humidities, and in aqueous media.
- the process disclosed herein provides stable crystalline form of laquinimod.
- stable crystalline form refers to stability of the crystalline form under the standard temperature and humidity conditions of testing of pharmaceutical products, wherein the stability is indicated by preservation of the original polymorphic form.
- Exemplary halogenated hydrocarbon solvents include, but are not limited to, methylene chloride, 1 ,2-dichloroethane, chloroform, carbon tetrachloride, and mixtures thereof.
- a specific halogenated hydrocarbon solvent is methylene chloride.
- Exemplary ester solvents include, but are not limited to, C 2 to C 6 alkyl acetates such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, tert-butyl acetate, ethyl formate, and mixtures thereof.
- Specific ester solvents are ethyl acetate, isopropyl acetate, and mixtures thereof.
- Step-(a) of providing a suspension of laquinimod includes suspending laquinimod in the solvent medium under stirring at below reflux temperature of the solvent medium used.
- the suspension is stirred at a temperature of about 30 0 C to about 100 0 C for at least 15 minutes and more specifically at about 40 0 C to about 8O 0 C for about 30 minutes to about 5 hours.
- reflux temperature means the temperature at which the solvent or solvent system refluxes or boils at atmospheric pressure.
- the suspension in step-(a) is prepared by reacting 1,2- dichloro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3-carboxylic acid with N-ethyl aniline in the presence of a suitable coupling agent, optionally in the presence of a base, in a suitable solvent under suitable conditions to produce a reaction mass containing crude laquinimod acid followed by usual work up such as washings, extractions, evaporations etc., and suspending the resulting crude laquinimod in the solvent medium under stirring at below reflux temperature of the solvent medium used, specifically at a temperature of about 30 0 C to about 100 0 C, and more specifically at about 4O 0 C to about 8O 0 C.
- the suspension in step-(a) is prepared by treating a pharmaceutically acceptable salt of laquinimod with an acid to liberate laquinimod acid and suspending the laquinimod acid in the solvent medium.
- compositions of laquinimod can be obtained from alkali or alkaline earth metals including sodium, calcium, potassium and magnesium, and more specifically sodium.
- the treatment of the pharmaceutically acceptable salt of laquinimod with acid is carried out in any solvent and the selection of solvent is not critical.
- solvents such as chlorinated solvents, hydrocarbon solvents, ether solvents, alcoholic solvents, ketonic solvents, ester solvents etc., can be used.
- the acid can be inorganic or organic.
- Specific acids are hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, propionic acid, phosphoric acid, succinic acid, maleic acid, fumaric acid, citric acid, glutaric acid, citraconic acid, glutaconic acid, tartaric acid, malic acid, ascorbic acid, and more specifically hydrochloric acid.
- the suspension in step-(b) is specifically cooled at a temperature of below 30 0 C under stirring for at least 15 minutes, and more specifically at a temperature of about 10 0 C to about 3O 0 C for about 30 minutes to 2 hours.
- the recovering in step-(c) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof.
- the crystalline Form A of laquinimod is recovered by filtration employing a filtration media of, for example, a silica gel or celite.
- the substantially pure laquinimod crystalline Form A obtained by above process may be further dried in, for example, a Vacuum Tray Dryer, a Rotocon Vacuum Dryer, a Vacuum Paddle Dryer or a pilot plant Rota vapor, to further lower residual solvents. Drying can be carried out under reduced pressure until the residual solvent content reduces to the desired amount such as an amount that is within the limits given by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ("ICH”) guidelines. In one embodiment, the drying is carried out at atmospheric pressure or reduced pressures, such as below about 200 mm Hg, or below about 50 mm Hg, at temperatures such as about 35 0 C to about 75 0 C.
- ICH International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
- the drying can be carried out for any desired time period that achieves the desired result, such as about 1 to 20 hours. Drying may also be carried out for shorter or longer periods of time depending on the product specifications. Temperatures and pressures will be chosen based on the volatility of the solvent being used and the foregoing should be considered as only a general guidance. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer and the like. Drying equipment selection is well within the ordinary skill in the art.
- the purity of the crystalline Form A of laquinimod obtained by the process disclosed herein is greater than about 99%, specifically greater than about 99.5%, more specifically greater than about 99.9%, and most specifically greater than about 99.95% as measured by
- the purity of the laquinimod crystalline Form A can be about 99% to about 99.95%, or about 99.5% to about 99.99%.
- crystalline Form Al a novel crystalline form of laquinimod sodium, designated as crystalline Form Al, characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 4; ii) a powder X-ray diffraction pattern having peaks at about 9.1, 10.7 and 11.2 ⁇ 0.2 degrees
- a process for the preparation of laquinimod sodium crystalline Form Al comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) stirring the solution at about 15-3O 0 C to form a first reaction mass; e) cooling the first reaction mass at below about 1O 0 C to form a second reaction mass; and f) recovering the crystalline Form Al of laquinimod sodium from the second reaction mass.
- the process can produce crystalline Form Al of laquinimod sodium in substantially pure form.
- substantially pure laquinimod sodium crystalline Form Al refers to the laquinimod sodium crystalline Form Al having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
- the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 25 ⁇ 2°C and at a relative humidity of about 60 ⁇ 5% for a period of at least one month. In still another embodiment, the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 25 ⁇ 2°C and at a relative humidity of about 60 ⁇ 5% for a period of 6 months.
- the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 40 ⁇ 2°C and at a relative humidity of about 75 ⁇ 5% for a period of at least one month.
- the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 40 ⁇ 2°C and at a relative humidity of about 75 ⁇ 5% for a period of 3 months.
- the stability of crystalline Form Al is measured by maintaining crystalline Form Al at a temperature of about 40 0 C at a relative humidity of about 75% for at least about 1 month, specifically for a period of 3 months, or at a temperature of about 25 0 C at a relative humidity of about 60% for a period of 6 months.
- the laquinimod sodium crystalline Form Al is a free-flowing solid, having a bulk density of at least about 0.30 g/ml, and specifically about 0.30 g/ml to about 0.35 g/ml.
- the laquinimod sodium crystalline Form Al has a tapped density of at least about 0.40 g/ml, and specifically about 0.45 g/ml to about 0.50 g/ml.
- the laquinimod sodium crystalline Form Al obtained by the process disclosed herein is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the crystalline Form Al of laquinimod sodium obtained by the process disclosed herein is suitable for formulating laquinimod sodium.
- Exemplary alcohol solvents used in step-(a) include, but are not limited to, C ] to C 6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof.
- Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically ethanol.
- Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the alcoholic solvent, or obtaining an existing solution from a previous processing step.
- the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 2O 0 C to about 8O 0 C and more specifically at about 2O 0 C to about 6O 0 C.
- the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution.
- the suspension of laquinimod is provided by suspending the laquinimod in the alcoholic solvent under stirring at a temperature of below about reflux temperature of the solvent used, specifically at about 2O 0 C to about 8O 0 C, and more specifically at about 20 0 C to about 4O 0 C.
- the suspension of laquinimod is prepared by reacting 1,2- dichloro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline ⁇ 3-carboxylic acid with N-ethyl aniline in the presence of a suitable coupling agent, optionally in the presence of a base, in a suitable solvent under suitable conditions to produce a reaction mass containing crude laquinimod acid followed by usual work up such as washings, extractions, evaporations etc., and suspending the resulting crude laquinimod in the alcoholic solvent under stirring at a temperature of below about reflux temperature of the solvent used, specifically at about 2O 0 C to about 8O 0 C, and more specifically at about 2O 0 C to about 4O 0 C.
- Combining of the suspension with aqueous sodium hydroxide solution is done in a suitable order, for example, the aqueous sodium hydroxide solution is added to the suspension, or alternatively, the suspension is added to the aqueous sodium hydroxide solution.
- the addition is, for example, carried out drop wise or in one portion or in more than one portion.
- the addition is specifically carried out at a temperature of below 50°C for at least 15 minutes, and more specifically at a temperature of about 15°C to about 35°C for about 30 minutes to about 2 hours.
- the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment.
- the carbon treatment or silica get treatment is carried out by methods known in the art, for example, by stirring the solution with finely powdered carbon or silica gel at a temperature of below about 7O 0 C for at least 15 minutes, specifically at a temperature of about 4O 0 C to about 7O 0 C for at least 30 minutes; and filtering the resulting mixture through hyflo to obtain a filtrate containing laquinimod sodium by removing finely powdered carbon or silica gel.
- finely powdered carbon is an active carbon.
- a specific mesh size of silica gel is 40-500 mesh, and more specifically 60-120 mesh.
- step-(d) The solution in step-(d) is specifically stirred for at least 1 hour, and more specifically for about 2 hours to about 6 hours, at a temperature of about 20°C to about 30 0 C.
- the first reaction mass in step-(e) is cooled under stirring at a temperature of about 0-10 0 C for at least 15 minutes, and specifically at about 0-5°C for about 30 minutes to about 4 hours.
- the recovering in step-(f) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof.
- the crystalline Form Al of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite.
- the substantially pure laquinimod sodium crystalline Form Al obtained by the above process is further dried as described hereinabove.
- an improved process for preparing laquinimod sodium crystalline Form A2 comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) stirring the solution at a temperature of about 20-30 0 C for at least 1 hour to produce a reaction mass; and e) recovering the crystalline Form A2 of laquinimod sodium from the reaction mass obtained in step-(d).
- the crystalline Form A2 of laquinimod sodium is characterized by at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 7; ii) a powder X-ray diffraction pattern having peaks at about 8.36, 25.10 and 29.35 ⁇ 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.22, 9.68, 10.00, 11.79, 13.37, 13.78, 14.08, 14.31, 14.62, 15.02, 15.73, 16.14, 16.74, 17.82, 18.20, 18.90, 20.07, 22.09, 23.17 and 24.08 ⁇ 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 8; v) an IR spectrum having absorption bands at about 3301, 2971, 2935, 1613, 1585, 1526,
- substantially pure laquinimod sodium crystalline Form A2 refers to the laquinimod sodium crystalline Form A2 having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
- Exemplary alcohol solvents used in step-(a) include, but are not limited to, C 1 to C 6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof.
- Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically ethanol, isopropyl alcohol and mixtures thereof.
- Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the alcoholic solvent, or obtaining an existing solution from a previous processing step.
- the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 20 0 C to about 80 0 C, and more specifically at about 2O 0 C to about 6O 0 C.
- the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution as described hereinabove.
- the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above.
- the solution in step-(d) is specifically stirred for at least 5 hours, more specifically for about 6 hours to about 30 hours, and most specifically for about 15 hours to about 25 hours, at a temperature of about 25°C to about 3O 0 C.
- the recovering in step-(e) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof.
- the crystalline Form A2 of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite.
- the substantially pure laquinimod sodium crystalline Form A2 obtained by the above process is further dried as described hereinabove.
- a novel crystalline form of laquinimod sodium designated as crystalline Form A3, characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 10; ii) a powder X-ray diffraction pattern having peaks at about 6.44, 6.65, 7.72 and 8.77 ⁇ 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 9.31, 9.60, 10.71, 11.14, 11.66, 13.25, 14.61, 15.32, 17.62, 17.98, 18.54, 19.21, 21.38, 22.11, 22.59, 23.43, 23.99, 25.04, 25.44 and 27.86 ⁇ 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 11 ; v) an IR spectrum having absorption bands at about 3368, 2970, 2936, 1615, 1583, 15
- a process for the preparation of laquinimod sodium crystalline Form A3, comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) admixing the solution with an anti-solvent; and e) recovering the crystalline Form A3 of laquinimod sodium from the reaction mass obtained in step-(d).
- the process can produce crystalline Form A3 of laquinimod sodium in substantially pure form.
- substantially pure laquinimod sodium crystalline Form A3 refers to the laquinimod sodium crystalline Form A3 having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
- the laquinimod sodium crystalline Form A3 is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the laquinimod sodium crystalline Form A3 disclosed herein is suitable for formulating laquinimod sodium.
- Exemplary alcohol solvents used in step-(a) include, but are not limited to, Ci to C 6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof.
- Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically ethanol.
- Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the alcoholic solvent, or obtaining an existing solution from a previous processing step.
- the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 20 0 C to about 80 0 C, and more specifically at about 2O 0 C to about 60 0 C.
- the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution as described hereinabove.
- the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above.
- exemplary anti-solvents used in step-(d) include, but are not limited to, an ether, a hydrocarbon, and mixtures thereof.
- exemplary ether solvents include, but are not limited to, diisopropyl ether, diethyl ether, tetrahydrofuran, dioxane, and the like, and mixtures thereof.
- Exemplary hydrocarbon solvents include, but are not limited to, n-pentane, n-hexane and n- heptane and their isomers, cyclohexane, toluene, xylene, and mixtures thereof.
- Specific anti- solvents are diisopropyl ether, diethyl ether and mixtures thereof.
- Anti-solvent refers to a solvent which when added to an existing solution of a substance reduces the solubility of the substance.
- step-(d) The admixing in step-(d) is done in a suitable order, for example, the solution is added to the anti-solvent, or alternatively, the anti-solvent is added to the solution.
- the addition is, for example, carried out drop wise or in one portion or in more than one portion.
- the addition is specifically carried out at a temperature of below 50°C for at least 15 minutes and more specifically at a temperature of about 15°C to about 35°C for about 20 minutes to about 2 hours.
- the resulting mass is stirred for at least 2 hours, more specifically for about 6 hours to about 30 hours, and most specifically for about 15 hours to about 25 hours, at a temperature of about 2O 0 C to about 30°C.
- the recovering in step-(e) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof.
- the crystalline Form A3 of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite.
- the substantially pure laquinimod sodium crystalline Form A3 obtained by the above process is further dried as described hereinabove.
- a novel crystalline form of laquinimod sodium designated as crystalline Form A4, characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 13; ii) a powder X-ray diffraction pattern having peaks at about 6.09, 7.46 and 10.42 ⁇ 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.82, 8.47, 10.12, 14.15, 16.10, 18.95, 22.66, 23.50, 25.84, 26.13, 28.24, 29.07, 29.81, 31.62 and 33.94 ⁇ 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 14; v) an IR spectrum having absorption bands at about 3413, 2974, 2935, 1612, 1584, 1524, 1495, 1413, 1377, 1346, 1327,
- a process for the preparation of laquinimod sodium crystalline Form A4 comprising: a) providing a solution of laquinimod sodium in a ketone solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; and d) isolating crystalline Form A4 of laquinimod sodium from the solution.
- the process can produce crystalline Form A4 of laquinimod sodium in substantially pure form.
- substantially pure laquinimod sodium crystalline Form A4 refers to the laquinimod sodium crystalline Form A4 having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
- the laquinimod sodium crystalline Form A4 is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the laquinimod sodium crystalline Form A4 disclosed herein is suitable for formulating laquinimod sodium.
- Exemplary ketone solvents used in step-(a) include, but are not limited to, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone and the like, and mixtures thereof.
- a specific ketone solvent is acetone.
- Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the ketone solvent, or obtaining an existing solution from a previous processing step.
- the laquinimod sodium is dissolved in the ketone solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 4O 0 C to about 80°C, and most specifically at about 5O 0 C to about 7O 0 C.
- the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable ketone solvent followed by combining the suspension with sodium hydroxide base and then heating the resulting mass to form a clear solution.
- the suspension of laquinimod is provided by the methods as described hereinabove.
- the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above.
- step-(d) The isolation of pure laquinimod sodium crystalline Form A4 in step-(d) is carried out by crystallization methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, or a combination thereof.
- the crystallization is carried out by cooling the solution at a temperature of below 3O 0 C, and more specifically at about 0 0 C to about 25 0 C.
- the solid obtained in step-(d) is recovered by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof.
- the crystalline Form A4 of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite.
- the substantially pure laquinimod sodium crystalline Form A4 obtained by the above process is further dried as described hereinabove.
- Amorphous form of laquinimod sodium is characterized by at least one, and specifically all, of the following properties: a powder XRD pattern substantially in accordance with Figure 16; an IR spectrum substantially in accordance with Figure 17; and an IR spectrum having absorption bands at about 3401, 2973, 2936, 1612, 1584, 1525, 1494, 1412, 1377, 1345, 1327, 1253, 1219, 1177, 1097, 813 and 698 ⁇ 2 cm "1 .
- the X-ray powder diffraction pattern shows no peaks, thus demonstrating the amorphous nature of the product.
- a process for the preparation of an amorphous form of laquinimod sodium comprising: a) providing a solution of laquinimod sodium in a solvent selected from the group consisting of an alcohol, a ketone, and mixtures thereof; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; and d) substantially removing the solvent from the solution to provide amorphous form of laquinimod sodium.
- substantially removing the solvent refers to at least 80%, specifically grater than about 85%, more specifically grater than about 90%, still more specifically grater than about 99%, and most specifically essentially complete (100%), removal of the solvent from the solvent solution.
- the process can produce amorphous form of laquinimod sodium in substantially pure form.
- substantially pure amorphous laquinimod sodium refers to the amorphous laquinimod sodium having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
- the amorphous laquinimod sodium obtained by the process disclosed herein is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the amorphous laquinimod sodium is suitable for formulating laquinimod sodium.
- Exemplary alcohol solvents used in step-(a) include, but are not limited to, Ci to C 6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof. Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically methanol.
- Exemplary ketone solvents used in step-(a) include, but are not limited to, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone and the like, and mixtures thereof. A specific ketone solvent is acetone.
- Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the solvent, or obtaining an existing solution from a previous processing step.
- the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 2O 0 C to about 80 0 C, and most specifically at about 2O 0 C to about 7O 0 C.
- the solution in step-(a) is prepared by providing a suspension of laquinimod in a solvent selected from the group consisting of an alcohol, a ketone, and mixtures thereof; combining the suspension with aqueous sodium hydroxide solution and optionally heating the resulting mass until to form a clear solution.
- the suspension of laquinimod is provided by the methods as described hereinabove.
- the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above.
- Removal of solvent in step-(d) is accomplished, for example, by substantially complete evaporation of the solvent, concentrating the solution or distillation of solvent, under inert atmosphere to obtain amorphous laquinimod sodium.
- the solvent is removed by evaporation.
- Evaporation can be achieved at sub-zero temperatures by lyophilisation or freeze-drying techniques.
- the solution may also be completely evaporated in, for example, a pilot plant Rota vapor, a Vacuum Paddle Dryer or in a conventional reactor under vacuum above about 720 mm Hg by flash evaporation techniques by using an agitated thin film dryer ("ATFD"), or evaporated by spray drying to obtain a dry amorphous powder.
- the distillation process can be performed at atmospheric pressure or reduced pressure.
- the solvent is removed at a pressure of about 760 mm Hg or less, more specifically at about 400 mm Hg or less, still more specifically at about 80 mm Hg or less, and most specifically from about 30 to about 80 mm Hg.
- Solvents can also be removed by spray-drying, in which a solution of laquinimod sodium is sprayed into the spray drier at the flow rate ranging from 10 to 300 ml/hr, specifically 40 to 200ml/hr.
- the air inlet temperature to the spray drier used may range from about 3O 0 C to about 150 0 C, specifically from about 65 0 C to about 110 0 C and the outlet air temperature used may range from about 30 0 C to about 90 0 C.
- Another suitable method is vertical agitated thin-film drying (or evaporation). Agitated thin film evaporation technology involves separating the volatile component using indirect heat transfer coupled with mechanical agitation of the flowing film under controlled conditions.
- the starting solution is fed from the top into a cylindrical space between a centered rotary agitator and an outside heating jacket.
- the rotor rotation agitates the downside-flowing solution while the heating jacket heats it.
- the substantially pure amorphous form of laquinimod sodium obtained by the above process is further dried as described hereinabove. Further encompassed herein is the use of the polymorphic forms of laquinimod and its sodium salt disclosed herein for the manufacture of a pharmaceutical composition together with a pharmaceutically acceptable carrier.
- a specific pharmaceutical composition of the polymorphic forms of laquinimod and its sodium salt is selected from a solid dosage form and an oral suspension.
- each one or a mixture of the solid state forms of laquinimod sodium (Form Al, Form A3, Form A4 and amorphous form) disclosed herein has a D 90 particle size of less than or equal to about 500 microns, specifically less than or equal to about 300 microns, more specifically less than or equal to about 200 microns, still more specifically less than or equal to about 100 microns, and most specifically less than or equal to about 15 microns.
- each one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein for use in the pharmaceutical compositions has a 90 volume-percent of the particles (D 90 ) of less than or equal to about 500 microns, specifically less than or equal to about 300 microns, more specifically less than or equal to about 200 microns, still more specifically less than or equal to about 100 microns, and most specifically less than or equal to about 15 microns.
- the particle sizes of the amorphous or polymorphic forms of laquinimod sodium can be achieved by a mechanical process of reducing the size of particles which includes any one or more of cutting, chipping, crushing, milling, grinding, micronizing, trituration or other particle size reduction methods known in the art, to bring the solid state form to the desired particle size range.
- a method for treating a patient suffering from diseases caused by autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis and, furthermore, diseases where pathologic inflammation plays a major role, such as asthma, atherosclerosis, stroke and Alzheimer's disease; comprising administering any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, or a pharmaceutical composition that comprises any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein along with pharmaceutically acceptable excipients.
- diseases caused by autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis and, furthermore, diseases where pathologic inflammation plays
- compositions comprising laquinimod crystalline Form A, and one or more pharmaceutically acceptable excipients.
- pharmaceutical compositions comprising laquinimod crystalline Form A prepared according to process disclosed herein and one or more pharmaceutically acceptable excipients.
- a process for preparing a pharmaceutical formulation comprising combining laquinimod crystalline Form A with one or more pharmaceutically acceptable excipients.
- compositions comprising a therapeutically effective amount of any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, and one or more pharmaceutically acceptable excipients.
- pharmaceutical compositions comprising any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium prepared according to processes disclosed herein and one or more pharmaceutically acceptable excipients.
- a process for preparing a pharmaceutical formulation comprising combining any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium prepared according to processes disclosed herein, with one or more pharmaceutically acceptable excipients.
- compositions comprise at least a therapeutically effective amount of any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein.
- Such pharmaceutical compositions may be administered to a mammalian patient in a dosage form, e.g., solid, liquid, powder, elixir, aerosol, syrups, injectable solution, etc.
- Dosage forms may be adapted for administration to the patient by oral, buccal, parenteral, ophthalmic, rectal and transdermal routes or any other acceptable route of administration.
- Oral dosage forms include, but are not limited to, tablets, pills, capsules, syrup, troches, sachets, suspensions, powders, lozenges, elixirs and the like.
- the amorphous or polymorphic forms of laquinimod sodium may also be administered as suppositories, ophthalmic ointments and suspensions, and parenteral suspensions, which are administered by other routes.
- the pharmaceutical compositions further contain one or more pharmaceutically acceptable excipients. Suitable excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field, e.g., the buffering agents, sweetening agents, binders, diluents, fillers, lubricants, wetting agents and disintegrants described hereinabove.
- a pharmaceutical composition comprising laquinimod sodium crystalline Form Al and one or more pharmaceutically acceptable excipients.
- a pharmaceutical composition comprising laquinimod sodium crystalline Form A3 and one or more pharmaceutically acceptable excipients.
- composition comprising laquinimod sodium crystalline Form A4 and one or more pharmaceutically acceptable excipients.
- a pharmaceutical composition comprising the amorphous form of laquinimod sodium and one or more pharmaceutically acceptable excipients.
- capsule dosage forms contain the amorphous or polymorphic forms of laquinimod sodium within a capsule which may be coated with gelatin. Tablets and powders may also be coated with an enteric coating. Suitable enteric coating include phthalic acid cellulose acetate, hydroxypropylmethyl cellulose phthalate, polyvinyl alcohol phthalate, carboxy methyl ethyl cellulose, a copolymer of styrene and maleic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, the coating agents may be employed with suitable plasticizers and/or extending agents.
- a coated capsule or tablet may have a coating on the surface thereof or may be a capsule or tablet comprising a powder or granules with an enteric-coating.
- compositions may have few or many components depending upon the tableting method used, the release rate desired and other factors.
- the compositions described herein may contain diluents such as cellulose-derived materials like powdered cellulose, microcrystalline cellulose, microfine cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose salts and other substituted and unsubstituted celluloses; starch; pregelatinized starch; inorganic diluents such calcium carbonate and calcium diphosphate and other diluents known to one of ordinary skill in the art.
- Suitable diluents include waxes, sugars (e.g. lactose) and sugar alcohols such as mannitol and sorbitol, acrylate polymers and copolymers, as well as pectin, dextrin and gelatin.
- excipients include binders, such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes; disintegrants such as sodium starch glycolate, crospovidone, low- substituted hydroxypropyl cellulose and others; lubricants like magnesium and calcium stearate and sodium stearyl fumarate; flavorings; sweeteners; preservatives; pharmaceutically acceptable dyes and glidants such as silicon dioxide.
- binders such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes
- disintegrants such as sodium starch glycolate, crospovidone, low- substituted hydroxypropyl cellulose and others
- lubricants like magnesium and calcium stearate and sodium stearyl fumarate
- flavorings sweeteners
- preservatives pharmaceutically acceptable dyes and
- Apparatus Water's HPLC system having alliance 2695 model pump and 2487 (UV) detector with Empower chromatography software or its equivalent. Chromatographic Parameters:
- Solution B Acetonitrile: Methanol - 50:50(v/v)
- FT-IR spectroscopy was carried out with a Perkin Elmer Spectrum 100 series spectrometer.
- a Perkin Elmer Spectrum 100 series spectrometer For the production of the KBr compacts approximately 2 mg of sample was powdered with 200 mg of KBr. The spectra were recorded in transmission mode ranging from 3800 to 450 cm *1 .
- the reaction mixture was heated to reflux temperature (40-45°C) and then stirred for 6 hours at reflux.
- the resulting mass was cooled to 25 -30° C followed by the addition of water (370 ml) and then stirred for 15 minutes.
- the resulting two layers were separated, the organic layer was washed with water (370 ml) at 25-30°C and then distilled out the methylene chloride under vacuum at 40-45 °C.
- methylene chloride (37 ml) and ethyl acetate (370 ml) was heated to 60-65 0 C and then stirred for 15 minutes at the same temperature.
- the resulting mass was cooled to 25-30°C followed by stirring for 1 hour.
- N-Ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide (35 gm) was suspended in ethanol (140 ml) at 20-25 0 C under stirring followed by the addition of freshly prepared sodium hydroxide solution (4.13 gm of sodium hydroxide in 11 ml of water) at 20-25 0 C and then stirred for 15-30 minutes at 25-30 0 C. The resulting solution was filtered through a hyfiow super cell bed and the bed was washed with ethanol (105 ml) at 25-3O 0 C.
- the resulting filtrate was seeded with pure laquinimod sodium (0.175 gm) and then stirred for 4 hours at 25-30 0 C.
- the resulting mass was cooled to 0-5 0 C followed by stirring for 2 hours at the same temperature.
- N-Ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide (18 gm) and ethanol (180 ml) were stirred at 25-30 0 C for 15 minutes followed by the addition of 40% sodium hydroxide solution (5.6 ml) at 25-30 0 C in 10 minutes. The resulted clear solution was stirred at 25-30°C for 20 hours. The precipitated white colored solid was filtered, washed with ethanol (20ml) and then dried at 55-6O 0 C to a constant weight to yield 13 gm of laquinimod sodium in crystalline Form A2.
- N-Ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide (15 gm) was suspended in isopropyl alcohol (100 ml) at 25-30°C under stirring followed by the addition of freshly prepared sodium hydroxide solution (1.4 gm of sodium hydroxide in 3.5 ml of water) at 20-25°C and then stirred for 15-30 minutes at 25-30°C. The resulting solution was filtered through a hyflow supercell bed and the bed was washed with isopropyl alcohol (50 ml) at 25-3O 0 C. The resulting filtrate was stirred for 20 hours at 25-3O 0 C.
- Laquinimod sodium (1.5 gm) was dissolved in methanol (10 ml) at 25-3O 0 C and stirred for 30 minutes. The resulting clear solution was filtered through a hyflow bed and the filtrate was added slowly to diisopropyl ether (500 ml) in 15 minutes at 25-3O 0 C. The resulting mass was stirred for 24 hours at 25-30 0 C. The separated white colored solid was filtered, washed with diisopropyl ether (20 ml) and then dried at 55-60 0 C to produce 1.3 gm of laquinimod sodium in crystalline Form A3.
- Laquinimod sodium (2 gm) was dissolved in acetone (10 ml) at 55-60°C and then stirred for 30 minutes. The resulted clear solution was cooled to 25-30 0 C in 30 minutes and the resulting mass was then stirred for 1 hour at 25-30 0 C. The separated solid was filtered and then dried at 53°C to a constant weight to produce 1.1 gm laquinimod sodium in crystalline Form A4.
- Example 7 Preparation of Amorphous form of Laquinimod Sodium
- Laquinimod sodium (1.5 gm) was dissolved in methanol (10 ml) and stirred for 30 minutes at 25-30°C. The resulted clear solution was filtered through hyflow bed. Methanol was distilled off under vacuum using rotary evaporator at 50-55 0 C to afford 1.2 gm of amorphous laquinimod sodium.
- Example 8 Stability of Laquinimod sodium Crystalline Form Al
- Laquinimod sodium crystalline Form Al was prepared according to the process exemplified in Example 2 and was packed in a self-sealing low-density polyethylene (LDPE) bag. The material was stored for 6 months at a relative humidity of about 60 ⁇ 5% at room temperature (at 25 ⁇ 2°C) and checked for polymorphic stability.
- LDPE low-density polyethylene
- the material was found to retain its polymorphic form after three months of holding, as indicated by maintenance of the original P-XRD pattern.
- Laquinimod sodium crystalline Form Al was prepared according to the process exemplified in Example 2 and was packed in a self-sealing low-density polyethylene (LDPE) bag. The material was stored for 3 months at a relative humidity of about 75 ⁇ 5% at a temperature of about 40 ⁇ 2°C and checked for polymorphic stability.
- LDPE low-density polyethylene
- the material was found to retain its polymorphic form after three months of holding, as indicated by maintenance of the original P-XRD pattern.
- crystalline polymorph refers to a crystal modification that can be characterized by analytical methods such as X-ray powder diffraction, IR-spectroscopy, differential scanning calorimetry (DSC) or by its melting point.
- stable crystalline form refers to stability of the crystalline form under the standard temperature and humidity conditions of testing of pharmaceutical products, wherein the stability is indicated by preservation of the original polymorphic form.
- amorphous means a solid without long-range crystalline order.
- Amorphous form of laquinimod sodium specifically contains less than about 10% crystalline forms of laquinimod sodium, more specifically less than 5% crystalline forms of laquinimod sodium, and still more specifically is essentially free of crystalline forms of laquinimod sodium.
- "Essentially free of crystalline forms of laquinimod sodium” means that no crystalline polymorph forms of laquinimod sodium can be detected within the limits of a powder X-ray diffractometer.
- pharmaceutically acceptable means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and includes that which is acceptable for veterinary use and/or human pharmaceutical use.
- composition is intended to encompass a drug product including the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions encompass any composition made by admixing the active ingredient, active ingredient dispersion or composite, additional active ingredient(s), and pharmaceutically acceptable excipients.
- terapéuticaally effective amount means the amount of a compound that, when administered to a mammal for treating a state, disorder or condition, is sufficient to effect such treatment.
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the mammal to be treated.
- delivering means providing a therapeutically effective amount of an active ingredient to a particular location within a host causing a therapeutically effective blood concentration of the active ingredient at the particular location. This can be accomplished, e.g., by topical, local or by systemic administration of the active ingredient to the host.
- buffering agent as used herein is intended to mean a compound used to resist a change in pH upon dilution or addition of acid of alkali.
- Such compounds include, by way of example and without limitation, potassium metaphosphate, potassium phosphate, monobasic sodium acetate and sodium citrate anhydrous and dehydrate and other such material known to those of ordinary skill in the art.
- sweetening agent as used herein is intended to mean a compound used to impart sweetness to a formulation.
- Such compounds include, by way of example and without limitation, aspartame, dextrose, glycerin, mannitol, saccharin sodium, sorbitol, sucrose, fructose and other such materials known to those of ordinary skill in the art.
- binder as used herein is intended to mean substances used to cause adhesion of powder particles in granulations.
- Such compounds include, by way of example and without limitation, acacia, alginic acid, tragacanth, carboxymethylcellulose sodium, polyvinylpyrrolidone, compressible sugar (e.g., NuTab), ethylcellulose, gelatin, liquid glucose, methylcellulose, pregelatinized starch, starch, polyethylene glycol, guar gum, polysaccharide, bentonites, sugars, invert sugars, poloxamers (PLURONIQTM) F68, PLURONICCTM) F 127), collagen, albumin, celluloses in non-aqueous solvents, polypropylene glycol, polyoxyethylene-polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, polyethylene oxide, microcrystalline cellulose, combinations thereof and other material known to those of ordinary skill in the art.
- filler is intended to mean inert substances used as fillers to create the desired bulk, flow properties, and compression characteristics in the preparation of solid dosage formulations.
- Such compounds include, by way of example and without limitation, dibasic calcium phosphate, kaolin, sucrose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, starch, combinations thereof and other such materials known to those of ordinary skill in the art.
- glidant as used herein is intended to mean agents used in solid dosage formulations to improve flow-properties during tablet compression and to produce an anti- caking effect.
- Such compounds include, by way of example and without limitation, colloidal silica, calcium silicate, magnesium silicate, silicon hydrogel, cornstarch, talc, combinations thereof and other such materials known to those of ordinary skill in the art.
- lubricant as used herein is intended to mean substances used in solid dosage formulations to reduce friction during compression of the solid dosage.
- Such compounds include, by way of example and without limitation, calcium stearate, magnesium stearate, mineral oil, stearic acid, zinc stearate, combinations thereof and other such materials known to those of ordinary skill in the art.
- disintegrant as used herein is intended to mean a compound used in solid dosage formulations to promote the disruption of the solid mass into smaller particles which are more readily dispersed or dissolved.
- exemplary disintegrants include, by way of example and without limitation, starches such as corn starch, potato starch, pregelatinized, sweeteners, clays, such as bentonite, microcrystalline cellulose (e.g., Avicel(TM)), carsium (e.g., Amberlite(TM)), alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pectin, tragacanth, combinations thereof and other such materials known to those of ordinary skill in the art.
- starches such as corn starch, potato starch, pregelatinized, sweeteners, clays, such as bentonite, microcrystalline cellulose (e.g., Avicel(TM)), carsium (e.g., Amberlite(TM)), alginates, sodium starch glycolate, gums
- wetting agent as used herein is intended to mean a compound used to aid in attaining intimate contact between solid particles and liquids.
- exemplary wetting agents include, by way of example and without limitation, gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), poly oxy ethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, (e.g., TWEEN(TM)s), polyethylene glycols, polyoxyethylene stearates colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxye
- micronization means a process or method by which the size of a population of particles is reduced.
- micron or “ ⁇ m” refers to "micrometer” which is 1 x 10 '6 meter.
- crystalline particles means any combination of single crystals, aggregates and agglomerates.
- P.S.D particle Size Distribution
- Dx means that X percent of the particles have a diameter less than a specified diameter D.
- a Dg 0 or d(0.9) of less than 300 microns means that 90 volume- percent of the particles in a composition have a diameter less than 300 microns.
- substantially pure is meant having purity greater than about 98%, specifically greater than about 99%, and more specifically greater than about 99.9% measured by HPLC.
- wt% refers to percent by weight. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein is a novel crystalline form of laquinimod, process for the preparation, pharmaceutical compositions, and method of treating thereof. Provided also herein are novel amorphous and polymorphic forms of laquinimod sodium, process for the preparation, pharmaceutical compositions, and method of treating thereof.
Description
NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT
CROSS REFERENCE TO RELATED APPLICATION
This application claims the benefit of priority to Indian provisional application No. 1602/CHE/2008, filed on July 1, 2008, which is incorporated herein by reference in its entirety.
FIELD OF THE DISCLOSURE
The present disclosure relates to a novel crystalline form of laquinimod, process for the preparation, pharmaceutical compositions, and method of treating thereof. The present disclosure further relates to novel solid state forms of laquinimod sodium, process for the preparation, pharmaceutical compositions, and method of treating thereof.
BACKGROUND
U.S. Patent No. 6,077,851 discloses a variety of quinoline-3-carboxamide derivatives and their salts, processes for their preparation, pharmaceutical compositions comprising the derivatives, and method of use thereof. These compounds are useful for clinical treatment of diseases resulting from autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis and, furthermore, diseases where pathologic inflammation plays a major role, such as asthma, atherosclerosis, stroke and Alzheimer's disease. Of these compounds, N-ethyl-N- phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide is important, since it is well-known as a pharmaceutically active substance under the name of Laquinimod. Laquinimod is a promising immunomodulatory agent and useful for the treatment of multiple sclerosis and its manifestations. Laquinimod is represented by the following structural formula:
Processes for the preparation of laquinimod and its sodium salt are disclosed in U.S. Patent Nos. 6,077,851 and 6,875,869.
U.S. Patent No. 6,077,851 (hereinafter referred to as the '851 patent) describes several synthetic routes for preparing laquinimod. According to a first synthetic process, laquinimod is prepared by the reaction of l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3- carboxylic acid ethyl ester with N-ethylaniline in a suitable solvent such as toluene, xylene and the like, to produce a reaction mass containing laquinimod, followed by distillation of ethanol formed during the reaction and then subjected to usual work up to produce laquinimod, which is then converted into its sodium salt.
According to a second synthetic process as described in the '851 patent, laquinimod is prepared by the reaction of 5-chloro isatoic anhydride with N-ethyl-N-phenylcarbamoyl acetic acid ethyl ester in the presence of methyl iodide and a strong base such as sodium hydride in a suitable solvent such as N,N-dimethylacetamide.
According to a third synthetic process as described in the '851 patent, laquinimod is prepared by the reaction of l,2-dihydro-4~hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3- carboxylic acid with N-ethylaniline using coupling reagents such as carbodiimides and thionyl chloride in the presence of triethylamine to produce laquinimod.
Laquinimod obtained by the processes described in the '851 patent is further recrystallized from methanol to produce laquinimod with greater than 95% purity.
The '851 patent makes no reference to the existence of specific polymorphic forms of laquinimod sodium. According to the embodiments exemplified, the product is obtained by suspending laquinimod in ethanol, adding 5M sodium hydroxide solution to the suspension by adjusting the pH to 8-12, stirring the reaction mixture for 30 minutes at ambient temperature and recovering the precipitated laquinimod sodium.
U.S. Patent No. 6,875,869 (hereinafter referred to as the '869 patent) describes an improved process for the preparation of laquinimod comprising reacting 1 ,2-dihydro-4- hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3-carboxylic acid methyl ester with N- ethylaniline in the presence of a solvent selected from straight or branched alkanes and cycloalkanes or mixtures thereof with a boiling point between 80°C and 200°C, specifically n-heptane, n-octane or mixtures thereof.
PCT Publication No. WO 2007/047863 discloses a process for recrystallization of laquinimod sodium comprising dissolving laquinimod sodium in water to form an aqueous solution, concentrating the solution to form a concentrated solution, adding a water-miscible anti-solvent to the concentrated solution to form laquinimod sodium crystals, and isolating the laquinimod sodium crystals.
Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and /or conformations of the molecule in the crystal lattice. Thus, in the strict sense, polymorphs are different crystalline forms of the same pure substance in which the molecules have different arrangements and / or configurations of the molecules". Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph. It is therefore important to investigate all solid forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and infrared spectrometry (IR). Solvent medium and mode of isolation play very important role in obtaining one polymorphic form over another.
It has been disclosed in the art that the amorphous forms of a number of pharmaceutical compounds exhibit superior dissolution characteristics and in some cases different bioavailability patterns compared to crystalline forms [Konno T., Chem. Pharm. Bull., 38, 2003 (1990)]. For some therapeutic indications one bioavailability pattern may be favored over another.
The discovery of new polymorphic forms of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic.
Hence, there is a need in the art for novel and stable solid state forms of laquinimod and its sodium salt.
SUMMARY
We have now surprisingly and unexpectedly discovered novel polymorphic forms of laquinimod acid and its sodium salt, different from the material obtained according to the teachings of the '851 patent, and having adequate stability and good dissolution properties.
The process for the preparation of laquinimod sodium described in Example 2 of the '851 patent yields a crystalline form, which we denote as Form A2, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 7.22, 8.36, 9.68, 10.00, 11.79, 13.37, 13.78, 14.08, 14.31, 14.62, 15.02, 15.73, 16.14, 16.74, 17.82, 18.20, 18.90, 20.07, 22.09, 23.17, 24.08, 25.10 and 29.35 ± 0.2 degrees substantially as depicted in Figure 7, and further characterized by an IR spectrum having absorption bands at about 3301, 2971, 2935, 1613, 1585, 1526, 1495, 1414, 1378, 1347, 1328, 1253, 1220, 1178, 1098, 811 and 700 ± 2 cm"1 substantially as depicted in Figure 8, different from the laquinimod sodium crystal forms of the present invention. In one aspect, provided herein is a novel and stable crystalline form of laquinimod acid, designated as laquinimod crystalline Form A, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 7.15, 12.58, 14.84, 25.09 and 26.38 ± 0.2 degrees.
In another aspect, encompassed herein is a process for preparing the substantially pure and stable crystalline Form A of laquinimod.
It has also been found that the laquinimod crystalline Form A is stable and consistently reproducible and thus useful in the preparation of laquinimod sodium in high purity.
In another aspect, provided herein is a novel and stable crystalline form of laquinimod sodium, designated as laquinimod sodium crystalline Form Al, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 9.1, 10.7 and 11.2 ± 0.2 degrees.
In another aspect, encompassed herein is a process for preparing the substantially pure and stable crystalline Form Al of laquinimod sodium. The novel crystalline Form Al of laquinimod sodium is consistently reproducible, does not have the tendency to convert to other forms and found to be more stable even after being stored at a temperature of about 40°C at a relative humidity of about 75% for at least about 1 month, specifically for a period of 3 months, or at a temperature of about 250C at a relative humidity of about 60% for at least about 6 months. Moreover, the crystalline Form Al of laquinimod sodium has a tapped density of about 0.4 g/ml to about 0.5 g/ml, is less electrostatic, and has good flow properties which is particularly suitable for bulk preparation and handling. The laquinimod sodium crystalline Form Al exhibits properties making it suitable for formulating laquinimod sodium.
In another aspect, encompassed herein is a novel process for preparing substantially pure crystalline Form A2 of laquinimod sodium.
In another aspect, provided herein is a novel and stable crystalline form of laquinimod sodium, designated as laquinimod sodium crystalline Form A3, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 6.44, 6.65, 7.72 and 8.77 ± 0.2 degrees.
In another aspect, encompassed herein is a process for preparing the substantially pure and stable crystalline Form A3 of laquinimod sodium.
In another aspect, provided herein is a novel and stable crystalline form of laquinimod sodium, designated as laquinimod sodium crystalline Form A4, characterized by an X-ray powder diffraction pattern having peaks expressed as 2-theta angle positions at about 6.09, 7.46 and 10.42 ± 0.2 degrees.
In another aspect, encompassed herein is a process for preparing the substantially pure and stable crystalline Form A4 of laquinimod sodium. In another aspect, provided herein is a novel and stable amorphous form of laquinimod sodium and use thereof for the preparation of laquinimod sodium.
In another aspect, encompassed herein is a process for preparing the substantially pure and stable amorphous form of laquinimod sodium.
In another aspect, provided herein is a pharmaceutical composition comprising laquinimod crystalline Form A disclosed herein and one or more pharmaceutically acceptable excipients.
In yet further aspect, encompassed herein is a process for preparing a pharmaceutical formulation comprising combining laquinimod crystalline Form A with one or more pharmaceutically acceptable excipients. In another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, and one or more pharmaceutically acceptable excipients.
In another aspect, provided herein is a pharmaceutical composition comprising any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium prepared according to processes disclosed herein and one or more pharmaceutically acceptable excipients.
In yet another aspect, encompassed herein is a process for preparing a pharmaceutical formulation comprising combining any one or a mixture of the amorphous or polymorphic
forms of laquinimod sodium prepared according to processes disclosed herein, with one or more pharmaceutically acceptable excipients.
In another aspect, provided herein is a method for treating a patient suffering from diseases caused by autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis and, furthermore, diseases where pathologic inflammation plays a major role, such as asthma, atherosclerosis, stroke and Alzheimer's disease; comprising administering any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, or a pharmaceutical composition that comprises any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein along with pharmaceutically acceptable excipients.
In still further aspect, each one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein for use in the pharmaceutical compositions has a 90 volume-percent of the particles (D90) of less than or equal to about 500 microns, specifically less than or equal to about 300 microns, more specifically less than or equal to about 200 microns, still more specifically less than or equal to about 100 microns, and most specifically less than or equal to about 15 microns.
BRIEF DESCRIPTION OF THE DRAWINGS Figure l is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod crystalline
Form A.
Figure 2 is a characteristic infra red (IR) spectrum of laquinimod crystalline Form A.
Figure 3 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod crystalline Form A. Figure 4 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form Al .
Figure 5 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
Al .
Figure 6 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form Al .
Figure 7 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form A2.
Figure 8 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
A2.
Figure 9 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form A2.
Figure 10 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form A3. Figure 11 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
A3.
Figure 12 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form A3.
Figure 13 is a characteristic powder X-ray diffraction (XRD) pattern of laquinimod sodium crystalline Form A4.
Figure 14 is a characteristic infra red (IR) spectrum of laquinimod sodium crystalline Form
A4.
Figure 15 is a characteristic differential scanning calorimetric (DSC) thermogram of laquinimod sodium crystalline Form A4. Figure 16 is a characteristic powder X-ray diffraction (XRD) pattern of amorphous laquinimod sodium.
Figure 17 is a characteristic infra red (IR) spectrum of amorphous laquinimod sodium.
DETAILED DESCRIPTION According to one aspect, there is provided a novel crystalline form of laquinimod acid, designated as laquinimod crystalline Form A, characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 1 ; ii) a powder X-ray diffraction pattern having peaks at about 7.15, 12.58, 14.84, 25.09 and 26.38 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 6.19, 8.78, 14.04, 14.37, 15.36, 16.20, 18.48, 18.81, 20.44, 20.73, 21.71, 23.21, 23.50, 23.76, 28.96 and 31.08 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 2; v) an IR spectrum having absorption bands at about 3081, 2976, 1647, 1617, 1586, 1562,
1496, 1378, 1327, 1303, 1237, 1197, 812 and 701 ± 2 cm"1; and vi) a DSC thermogram having an endotherm peak at about 240°C substantially as depicted in Figure 3.
According to another aspect, there is provided a process for the preparation of a crystalline Form A of laquinimod, comprising: a) providing a suspension of N-ethyl-N-phenyl- 1 ,2-dihydro-4-hydroxy-5-chloro- 1 -methyl-2- oxoquinoline-3-carboxamide (laquinimod or laquinimod acid) in a solvent medium comprising an ester solvent and a chlorinated hydrocarbon solvent; b) optionally, cooling the suspension obtained in step-(a); and c) recovering crystalline Form A of laquinimod from the suspension.
The process can produce crystalline Form A of laquinimod in substantially pure form.
The term "substantially pure laquinimod crystalline Form A" refers to the laquinimod crystalline Form A having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.3% and still more specifically greater than about 99.5% (measured by HPLC).
The laquinimod crystalline Form A is stable, consistently reproducible, and is particularly suitable for bulk preparation and handling. Moreover, the crystalline Form A of laquinimod is useful intermediate in the preparation of laquinimod sodium in high purity.
The crystalline Form A of laquinimod has good flow properties and stable at room temperature, enhanced temperature, at relative high humidities, and in aqueous media.
In one embodiment, the process disclosed herein provides stable crystalline form of laquinimod. The term "stable crystalline form" refers to stability of the crystalline form under the standard temperature and humidity conditions of testing of pharmaceutical products, wherein the stability is indicated by preservation of the original polymorphic form.
Exemplary halogenated hydrocarbon solvents include, but are not limited to, methylene chloride, 1 ,2-dichloroethane, chloroform, carbon tetrachloride, and mixtures thereof. A specific halogenated hydrocarbon solvent is methylene chloride. Exemplary ester solvents include, but are not limited to, C2 to C6 alkyl acetates such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, tert-butyl acetate, ethyl formate, and mixtures thereof. Specific ester solvents are ethyl acetate, isopropyl acetate, and mixtures thereof.
Step-(a) of providing a suspension of laquinimod includes suspending laquinimod in the solvent medium under stirring at below reflux temperature of the solvent medium used. In one embodiment, the suspension is stirred at a temperature of about 300C to about 1000C for at least 15 minutes and more specifically at about 400C to about 8O0C for about 30 minutes to about 5 hours.
As used herein, "reflux temperature" means the temperature at which the solvent or solvent system refluxes or boils at atmospheric pressure.
In another embodiment, the suspension in step-(a) is prepared by reacting 1,2- dichloro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3-carboxylic acid with N-ethyl aniline in the presence of a suitable coupling agent, optionally in the presence of a base, in a suitable solvent under suitable conditions to produce a reaction mass containing crude laquinimod acid followed by usual work up such as washings, extractions, evaporations etc., and suspending the resulting crude laquinimod in the solvent medium under stirring at below reflux temperature of the solvent medium used, specifically at a temperature of about 300C to about 1000C, and more specifically at about 4O0C to about 8O0C.
Alternatively, the suspension in step-(a) is prepared by treating a pharmaceutically acceptable salt of laquinimod with an acid to liberate laquinimod acid and suspending the laquinimod acid in the solvent medium.
Pharmaceutically acceptable salts of laquinimod can be obtained from alkali or alkaline earth metals including sodium, calcium, potassium and magnesium, and more specifically sodium.
The treatment of the pharmaceutically acceptable salt of laquinimod with acid is carried out in any solvent and the selection of solvent is not critical. A wide variety of solvents such as chlorinated solvents, hydrocarbon solvents, ether solvents, alcoholic solvents, ketonic solvents, ester solvents etc., can be used.
The acid can be inorganic or organic. Specific acids are hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, propionic acid, phosphoric acid, succinic acid, maleic acid, fumaric acid, citric acid, glutaric acid, citraconic acid, glutaconic acid, tartaric acid, malic acid, ascorbic acid, and more specifically hydrochloric acid. The suspension in step-(b) is specifically cooled at a temperature of below 300C under stirring for at least 15 minutes, and more specifically at a temperature of about 100C to about 3O0C for about 30 minutes to 2 hours.
The recovering in step-(c) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof. In one embodiment, the crystalline Form A of laquinimod is recovered by filtration employing a filtration media of, for example, a silica gel or celite.
The substantially pure laquinimod crystalline Form A obtained by above process may be further dried in, for example, a Vacuum Tray Dryer, a Rotocon Vacuum Dryer, a Vacuum Paddle Dryer or a pilot plant Rota vapor, to further lower residual solvents. Drying can be
carried out under reduced pressure until the residual solvent content reduces to the desired amount such as an amount that is within the limits given by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ("ICH") guidelines. In one embodiment, the drying is carried out at atmospheric pressure or reduced pressures, such as below about 200 mm Hg, or below about 50 mm Hg, at temperatures such as about 350C to about 750C. The drying can be carried out for any desired time period that achieves the desired result, such as about 1 to 20 hours. Drying may also be carried out for shorter or longer periods of time depending on the product specifications. Temperatures and pressures will be chosen based on the volatility of the solvent being used and the foregoing should be considered as only a general guidance. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer and the like. Drying equipment selection is well within the ordinary skill in the art.
The purity of the crystalline Form A of laquinimod obtained by the process disclosed herein is greater than about 99%, specifically greater than about 99.5%, more specifically greater than about 99.9%, and most specifically greater than about 99.95% as measured by
HPLC. For example, the purity of the laquinimod crystalline Form A can be about 99% to about 99.95%, or about 99.5% to about 99.99%.
According to another aspect, there is provided a novel crystalline form of laquinimod sodium, designated as crystalline Form Al, characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 4; ii) a powder X-ray diffraction pattern having peaks at about 9.1, 10.7 and 11.2 ± 0.2 degrees
2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.25, 9.72, 10.03, 13.08, 13.91, 14.57, 14.99, 15.69, 16.12, 16.75, 17.57, 18.15, 19.16, 19.87, 20.44, 21.24, 21.68, 21.88, 22.98, 23.79, 24.63 and 25.63 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 5; v) an IR spectrum having absorption bands at about 3377, 3062, 2972, 2933, 1611, 1585, 1528, 1495, 1414, 1377, 1347, 1325, 1255, 1220, 1178, 1098, 811 and 697 ± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 6.
According to another aspect, there is provided a process for the preparation of laquinimod sodium crystalline Form Al, comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent;
b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) stirring the solution at about 15-3O0C to form a first reaction mass; e) cooling the first reaction mass at below about 1O0C to form a second reaction mass; and f) recovering the crystalline Form Al of laquinimod sodium from the second reaction mass. The process can produce crystalline Form Al of laquinimod sodium in substantially pure form.
The term "substantially pure laquinimod sodium crystalline Form Al" refers to the laquinimod sodium crystalline Form Al having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
In another embodiment, the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 25±2°C and at a relative humidity of about 60±5% for a period of at least one month. In still another embodiment, the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 25±2°C and at a relative humidity of about 60±5% for a period of 6 months.
In yet another embodiment, the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 40±2°C and at a relative humidity of about 75±5% for a period of at least one month.
In still another embodiment, the laquinimod sodium crystalline Form Al disclosed herein remains in the same crystalline form and stable, when stored at a temperature of about 40±2°C and at a relative humidity of about 75±5% for a period of 3 months.
The term "remains stable", as defined herein, refers to lack of formation of impurities, while being stored as described herein. The stability of crystalline Form Al is measured by maintaining crystalline Form Al at a temperature of about 400C at a relative humidity of about 75% for at least about 1 month, specifically for a period of 3 months, or at a temperature of about 250C at a relative humidity of about 60% for a period of 6 months.
In another embodiment, the laquinimod sodium crystalline Form Al is a free-flowing solid, having a bulk density of at least about 0.30 g/ml, and specifically about 0.30 g/ml to about 0.35 g/ml.
In another embodiment, the laquinimod sodium crystalline Form Al has a tapped density of at least about 0.40 g/ml, and specifically about 0.45 g/ml to about 0.50 g/ml.
The laquinimod sodium crystalline Form Al obtained by the process disclosed herein is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the crystalline Form Al of laquinimod sodium obtained by the process disclosed herein is suitable for formulating laquinimod sodium. Exemplary alcohol solvents used in step-(a) include, but are not limited to, C] to C6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof. Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically ethanol.
Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the alcoholic solvent, or obtaining an existing solution from a previous processing step.
In one embodiment, the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 2O0C to about 8O0C and more specifically at about 2O0C to about 6O0C. In another embodiment, the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution.
The suspension of laquinimod is provided by suspending the laquinimod in the alcoholic solvent under stirring at a temperature of below about reflux temperature of the solvent used, specifically at about 2O0C to about 8O0C, and more specifically at about 200C to about 4O0C. In one embodiment, the suspension of laquinimod is prepared by reacting 1,2- dichloro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline~3-carboxylic acid with N-ethyl aniline in the presence of a suitable coupling agent, optionally in the presence of a base, in a suitable solvent under suitable conditions to produce a reaction mass containing crude laquinimod acid followed by usual work up such as washings, extractions, evaporations etc., and suspending the resulting crude laquinimod in the alcoholic solvent under stirring at a temperature of below about reflux temperature of the solvent used, specifically at about 2O0C to about 8O0C, and more specifically at about 2O0C to about 4O0C.
Combining of the suspension with aqueous sodium hydroxide solution is done in a suitable order, for example, the aqueous sodium hydroxide solution is added to the suspension, or alternatively, the suspension is added to the aqueous sodium hydroxide solution. The addition is, for example, carried out drop wise or in one portion or in more than one portion. The addition is specifically carried out at a temperature of below 50°C for at
least 15 minutes, and more specifically at a temperature of about 15°C to about 35°C for about 30 minutes to about 2 hours.
The solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment. The carbon treatment or silica get treatment is carried out by methods known in the art, for example, by stirring the solution with finely powdered carbon or silica gel at a temperature of below about 7O0C for at least 15 minutes, specifically at a temperature of about 4O0C to about 7O0C for at least 30 minutes; and filtering the resulting mixture through hyflo to obtain a filtrate containing laquinimod sodium by removing finely powdered carbon or silica gel. Preferably, finely powdered carbon is an active carbon. A specific mesh size of silica gel is 40-500 mesh, and more specifically 60-120 mesh.
The solution in step-(d) is specifically stirred for at least 1 hour, and more specifically for about 2 hours to about 6 hours, at a temperature of about 20°C to about 300C.
In one embodiment, the first reaction mass in step-(e) is cooled under stirring at a temperature of about 0-100C for at least 15 minutes, and specifically at about 0-5°C for about 30 minutes to about 4 hours.
The recovering in step-(f) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof. In one embodiment, the crystalline Form Al of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite. The substantially pure laquinimod sodium crystalline Form Al obtained by the above process is further dried as described hereinabove.
According to another aspect, there is provided an improved process for preparing laquinimod sodium crystalline Form A2, comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) stirring the solution at a temperature of about 20-300C for at least 1 hour to produce a reaction mass; and e) recovering the crystalline Form A2 of laquinimod sodium from the reaction mass obtained in step-(d).
In one embodiment, the crystalline Form A2 of laquinimod sodium is characterized by at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 7;
ii) a powder X-ray diffraction pattern having peaks at about 8.36, 25.10 and 29.35 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.22, 9.68, 10.00, 11.79, 13.37, 13.78, 14.08, 14.31, 14.62, 15.02, 15.73, 16.14, 16.74, 17.82, 18.20, 18.90, 20.07, 22.09, 23.17 and 24.08 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 8; v) an IR spectrum having absorption bands at about 3301, 2971, 2935, 1613, 1585, 1526,
1495, 1414, 1378, 1347, 1328, 1253, 1220, 1178, 1098, 811 and 700 ± 2 cm'1; and vi) a DSC thermogram substantially in accordance with Figure 9. The process can produce crystalline Form A2 of laquinimod sodium in substantially pure form.
The term "substantially pure laquinimod sodium crystalline Form A2" refers to the laquinimod sodium crystalline Form A2 having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
Exemplary alcohol solvents used in step-(a) include, but are not limited to, C1 to C6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof. Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically ethanol, isopropyl alcohol and mixtures thereof.
Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the alcoholic solvent, or obtaining an existing solution from a previous processing step.
In one embodiment, the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 200C to about 800C, and more specifically at about 2O0C to about 6O0C.
In another embodiment, the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution as described hereinabove. In another embodiment, the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above.
The solution in step-(d) is specifically stirred for at least 5 hours, more specifically for about 6 hours to about 30 hours, and most specifically for about 15 hours to about 25 hours, at a temperature of about 25°C to about 3O0C.
The recovering in step-(e) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof. In one embodiment, the crystalline Form A2 of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite. The substantially pure laquinimod sodium crystalline Form A2 obtained by the above process is further dried as described hereinabove.
According to another aspect, there is provided a novel crystalline form of laquinimod sodium, designated as crystalline Form A3, characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 10; ii) a powder X-ray diffraction pattern having peaks at about 6.44, 6.65, 7.72 and 8.77 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 9.31, 9.60, 10.71, 11.14, 11.66, 13.25, 14.61, 15.32, 17.62, 17.98, 18.54, 19.21, 21.38, 22.11, 22.59, 23.43, 23.99, 25.04, 25.44 and 27.86 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 11 ; v) an IR spectrum having absorption bands at about 3368, 2970, 2936, 1615, 1583, 1526,
1495, 1412, 1377, 1344, 1326, 1253, 1218, 1177, 1097, 813 and 699 ± 2 cm'1; and vi) a DSC thermogram substantially in accordance with Figure 12. According to another aspect, there is provided a process for the preparation of laquinimod sodium crystalline Form A3, comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) admixing the solution with an anti-solvent; and e) recovering the crystalline Form A3 of laquinimod sodium from the reaction mass obtained in step-(d).
The process can produce crystalline Form A3 of laquinimod sodium in substantially pure form. The term "substantially pure laquinimod sodium crystalline Form A3" refers to the laquinimod sodium crystalline Form A3 having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
The laquinimod sodium crystalline Form A3 is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the laquinimod sodium crystalline Form A3 disclosed herein is suitable for formulating laquinimod sodium. Exemplary alcohol solvents used in step-(a) include, but are not limited to, Ci to C6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof. Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically ethanol.
Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the alcoholic solvent, or obtaining an existing solution from a previous processing step.
In one embodiment, the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 200C to about 800C, and more specifically at about 2O0C to about 600C. In another embodiment, the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution as described hereinabove.
In another embodiment, the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above. Exemplary anti-solvents used in step-(d) include, but are not limited to, an ether, a hydrocarbon, and mixtures thereof. Exemplary ether solvents include, but are not limited to, diisopropyl ether, diethyl ether, tetrahydrofuran, dioxane, and the like, and mixtures thereof. Exemplary hydrocarbon solvents include, but are not limited to, n-pentane, n-hexane and n- heptane and their isomers, cyclohexane, toluene, xylene, and mixtures thereof. Specific anti- solvents are diisopropyl ether, diethyl ether and mixtures thereof.
The term "Anti-solvent" refers to a solvent which when added to an existing solution of a substance reduces the solubility of the substance.
The admixing in step-(d) is done in a suitable order, for example, the solution is added to the anti-solvent, or alternatively, the anti-solvent is added to the solution. The addition is, for example, carried out drop wise or in one portion or in more than one portion. The addition is specifically carried out at a temperature of below 50°C for at least 15 minutes and more specifically at a temperature of about 15°C to about 35°C for about 20 minutes to about 2 hours. After completion of addition process, the resulting mass is stirred for at least 2 hours,
more specifically for about 6 hours to about 30 hours, and most specifically for about 15 hours to about 25 hours, at a temperature of about 2O0C to about 30°C.
The recovering in step-(e) is carried out by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof. In one embodiment, the crystalline Form A3 of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite.
The substantially pure laquinimod sodium crystalline Form A3 obtained by the above process is further dried as described hereinabove.
According to another aspect, there is provided a novel crystalline form of laquinimod sodium, designated as crystalline Form A4, characterized by at least one, and specifically all, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 13; ii) a powder X-ray diffraction pattern having peaks at about 6.09, 7.46 and 10.42 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.82, 8.47, 10.12, 14.15, 16.10, 18.95, 22.66, 23.50, 25.84, 26.13, 28.24, 29.07, 29.81, 31.62 and 33.94 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 14; v) an IR spectrum having absorption bands at about 3413, 2974, 2935, 1612, 1584, 1524, 1495, 1413, 1377, 1346, 1327, 1253, 1219, 1177, 1097, 811 and 698 ± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 15.
According to another aspect, there is provided a process for the preparation of laquinimod sodium crystalline Form A4, comprising: a) providing a solution of laquinimod sodium in a ketone solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; and d) isolating crystalline Form A4 of laquinimod sodium from the solution.
The process can produce crystalline Form A4 of laquinimod sodium in substantially pure form. The term "substantially pure laquinimod sodium crystalline Form A4" refers to the laquinimod sodium crystalline Form A4 having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC).
The laquinimod sodium crystalline Form A4 is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the laquinimod sodium crystalline Form A4 disclosed herein is suitable for formulating laquinimod sodium. Exemplary ketone solvents used in step-(a) include, but are not limited to, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone and the like, and mixtures thereof. A specific ketone solvent is acetone.
Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the ketone solvent, or obtaining an existing solution from a previous processing step.
In one embodiment, the laquinimod sodium is dissolved in the ketone solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 4O0C to about 80°C, and most specifically at about 5O0C to about 7O0C.
In another embodiment, the solution in step-(a) is prepared by providing a suspension of laquinimod in a suitable ketone solvent followed by combining the suspension with sodium hydroxide base and then heating the resulting mass to form a clear solution.
In one embodiment, the suspension of laquinimod is provided by the methods as described hereinabove.
In another embodiment, the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above.
The isolation of pure laquinimod sodium crystalline Form A4 in step-(d) is carried out by crystallization methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, or a combination thereof.
In one embodiment, the crystallization is carried out by cooling the solution at a temperature of below 3O0C, and more specifically at about 00C to about 250C.
The solid obtained in step-(d) is recovered by methods such as filtration, filtration under vacuum, decantation, centrifugation, or a combination thereof. In one embodiment, the crystalline Form A4 of laquinimod sodium is recovered by filtration employing a filtration media of, for example, a silica gel or celite. The substantially pure laquinimod sodium crystalline Form A4 obtained by the above process is further dried as described hereinabove.
According to another aspect, there is provided a stable and substantially pure amorphous form of laquinimod sodium.
Amorphous form of laquinimod sodium is characterized by at least one, and specifically all, of the following properties: a powder XRD pattern substantially in accordance with Figure 16; an IR spectrum substantially in accordance with Figure 17; and an IR spectrum having absorption bands at about 3401, 2973, 2936, 1612, 1584, 1525, 1494, 1412, 1377, 1345, 1327, 1253, 1219, 1177, 1097, 813 and 698 ± 2 cm"1. The X-ray powder diffraction pattern shows no peaks, thus demonstrating the amorphous nature of the product.
According to another aspect, there is provided a process for the preparation of an amorphous form of laquinimod sodium, comprising: a) providing a solution of laquinimod sodium in a solvent selected from the group consisting of an alcohol, a ketone, and mixtures thereof; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; and d) substantially removing the solvent from the solution to provide amorphous form of laquinimod sodium. The term "substantially removing" the solvent refers to at least 80%, specifically grater than about 85%, more specifically grater than about 90%, still more specifically grater than about 99%, and most specifically essentially complete (100%), removal of the solvent from the solvent solution.
The process can produce amorphous form of laquinimod sodium in substantially pure form.
The term "substantially pure amorphous laquinimod sodium" refers to the amorphous laquinimod sodium having purity greater than about 98%, specifically greater than about 99%, more specifically greater than about 99.5% and still more specifically greater than about 99.9% (measured by HPLC). The amorphous laquinimod sodium obtained by the process disclosed herein is stable, consistently reproducible and has good flow properties, and is particularly suitable for bulk preparation and handling, and hence, the amorphous laquinimod sodium is suitable for formulating laquinimod sodium.
Exemplary alcohol solvents used in step-(a) include, but are not limited to, Ci to C6 straight or branched chain alcohol solvents such as methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof. Specific alcohol solvents are methanol, ethanol, isopropyl alcohol and mixtures thereof, and more specifically methanol. Exemplary ketone solvents used in step-(a) include, but are not limited to, acetone, methyl ethyl ketone,
methyl isobutyl ketone, methyl tert-butyl ketone and the like, and mixtures thereof. A specific ketone solvent is acetone.
Step-(a) of providing a solution of laquinimod sodium includes dissolving laquinimod sodium in the solvent, or obtaining an existing solution from a previous processing step. In one embodiment, the laquinimod sodium is dissolved in the solvent at a temperature of below about reflux temperature of the solvent used, specifically at about 2O0C to about 800C, and most specifically at about 2O0C to about 7O0C.
In another embodiment, the solution in step-(a) is prepared by providing a suspension of laquinimod in a solvent selected from the group consisting of an alcohol, a ketone, and mixtures thereof; combining the suspension with aqueous sodium hydroxide solution and optionally heating the resulting mass until to form a clear solution.
In one embodiment, the suspension of laquinimod is provided by the methods as described hereinabove.
In another embodiment, the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment as described above.
Removal of solvent in step-(d) is accomplished, for example, by substantially complete evaporation of the solvent, concentrating the solution or distillation of solvent, under inert atmosphere to obtain amorphous laquinimod sodium.
In one embodiment, the solvent is removed by evaporation. Evaporation can be achieved at sub-zero temperatures by lyophilisation or freeze-drying techniques. The solution may also be completely evaporated in, for example, a pilot plant Rota vapor, a Vacuum Paddle Dryer or in a conventional reactor under vacuum above about 720 mm Hg by flash evaporation techniques by using an agitated thin film dryer ("ATFD"), or evaporated by spray drying to obtain a dry amorphous powder. The distillation process can be performed at atmospheric pressure or reduced pressure.
Specifically, the solvent is removed at a pressure of about 760 mm Hg or less, more specifically at about 400 mm Hg or less, still more specifically at about 80 mm Hg or less, and most specifically from about 30 to about 80 mm Hg.
Solvents can also be removed by spray-drying, in which a solution of laquinimod sodium is sprayed into the spray drier at the flow rate ranging from 10 to 300 ml/hr, specifically 40 to 200ml/hr. The air inlet temperature to the spray drier used may range from about 3O0C to about 1500C, specifically from about 650C to about 1100C and the outlet air temperature used may range from about 300C to about 900C.
Another suitable method is vertical agitated thin-film drying (or evaporation). Agitated thin film evaporation technology involves separating the volatile component using indirect heat transfer coupled with mechanical agitation of the flowing film under controlled conditions. In vertical agitated thin-film drying (or evaporation) (ATFD-V), the starting solution is fed from the top into a cylindrical space between a centered rotary agitator and an outside heating jacket. The rotor rotation agitates the downside-flowing solution while the heating jacket heats it.
The substantially pure amorphous form of laquinimod sodium obtained by the above process is further dried as described hereinabove. Further encompassed herein is the use of the polymorphic forms of laquinimod and its sodium salt disclosed herein for the manufacture of a pharmaceutical composition together with a pharmaceutically acceptable carrier.
A specific pharmaceutical composition of the polymorphic forms of laquinimod and its sodium salt is selected from a solid dosage form and an oral suspension. In one embodiment, each one or a mixture of the solid state forms of laquinimod sodium (Form Al, Form A3, Form A4 and amorphous form) disclosed herein has a D90 particle size of less than or equal to about 500 microns, specifically less than or equal to about 300 microns, more specifically less than or equal to about 200 microns, still more specifically less than or equal to about 100 microns, and most specifically less than or equal to about 15 microns.
In another embodiment, each one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein for use in the pharmaceutical compositions has a 90 volume-percent of the particles (D90) of less than or equal to about 500 microns, specifically less than or equal to about 300 microns, more specifically less than or equal to about 200 microns, still more specifically less than or equal to about 100 microns, and most specifically less than or equal to about 15 microns.
In another embodiment, the particle sizes of the amorphous or polymorphic forms of laquinimod sodium can be achieved by a mechanical process of reducing the size of particles which includes any one or more of cutting, chipping, crushing, milling, grinding, micronizing, trituration or other particle size reduction methods known in the art, to bring the solid state form to the desired particle size range.
According to another aspect, there is provided a method for treating a patient suffering from diseases caused by autoimmunity such as multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel
disease and psoriasis and, furthermore, diseases where pathologic inflammation plays a major role, such as asthma, atherosclerosis, stroke and Alzheimer's disease; comprising administering any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, or a pharmaceutical composition that comprises any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein along with pharmaceutically acceptable excipients.
According to another aspect, there is provided pharmaceutical compositions comprising laquinimod crystalline Form A, and one or more pharmaceutically acceptable excipients. According to another aspect, there is provided pharmaceutical compositions comprising laquinimod crystalline Form A prepared according to process disclosed herein and one or more pharmaceutically acceptable excipients.
According to another aspect, there is provided a process for preparing a pharmaceutical formulation comprising combining laquinimod crystalline Form A with one or more pharmaceutically acceptable excipients.
According to another aspect, there is provided pharmaceutical compositions comprising a therapeutically effective amount of any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein, and one or more pharmaceutically acceptable excipients. According to another aspect, there is provided pharmaceutical compositions comprising any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium prepared according to processes disclosed herein and one or more pharmaceutically acceptable excipients.
According to another aspect of the present invention, there is provided a process for preparing a pharmaceutical formulation comprising combining any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium prepared according to processes disclosed herein, with one or more pharmaceutically acceptable excipients.
Yet in another embodiment, pharmaceutical compositions comprise at least a therapeutically effective amount of any one or a mixture of the amorphous or polymorphic forms of laquinimod sodium disclosed herein. Such pharmaceutical compositions may be administered to a mammalian patient in a dosage form, e.g., solid, liquid, powder, elixir, aerosol, syrups, injectable solution, etc. Dosage forms may be adapted for administration to the patient by oral, buccal, parenteral, ophthalmic, rectal and transdermal routes or any other acceptable route of administration. Oral dosage forms include, but are not limited to, tablets,
pills, capsules, syrup, troches, sachets, suspensions, powders, lozenges, elixirs and the like. The amorphous or polymorphic forms of laquinimod sodium may also be administered as suppositories, ophthalmic ointments and suspensions, and parenteral suspensions, which are administered by other routes. The pharmaceutical compositions further contain one or more pharmaceutically acceptable excipients. Suitable excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field, e.g., the buffering agents, sweetening agents, binders, diluents, fillers, lubricants, wetting agents and disintegrants described hereinabove. In another embodiment, there is provided a pharmaceutical composition comprising laquinimod sodium crystalline Form Al and one or more pharmaceutically acceptable excipients.
In another embodiment, there is provided a pharmaceutical composition comprising laquinimod sodium crystalline Form A3 and one or more pharmaceutically acceptable excipients.
In another embodiment, there is provided a pharmaceutical composition comprising laquinimod sodium crystalline Form A4 and one or more pharmaceutically acceptable excipients.
In another embodiment, there is provided a pharmaceutical composition comprising the amorphous form of laquinimod sodium and one or more pharmaceutically acceptable excipients.
In one embodiment, capsule dosage forms contain the amorphous or polymorphic forms of laquinimod sodium within a capsule which may be coated with gelatin. Tablets and powders may also be coated with an enteric coating. Suitable enteric coating include phthalic acid cellulose acetate, hydroxypropylmethyl cellulose phthalate, polyvinyl alcohol phthalate, carboxy methyl ethyl cellulose, a copolymer of styrene and maleic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, the coating agents may be employed with suitable plasticizers and/or extending agents. A coated capsule or tablet may have a coating on the surface thereof or may be a capsule or tablet comprising a powder or granules with an enteric-coating.
Tableting compositions may have few or many components depending upon the tableting method used, the release rate desired and other factors. For example, the compositions described herein may contain diluents such as cellulose-derived materials like powdered cellulose, microcrystalline cellulose, microfine cellulose, methyl cellulose, ethyl
cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose salts and other substituted and unsubstituted celluloses; starch; pregelatinized starch; inorganic diluents such calcium carbonate and calcium diphosphate and other diluents known to one of ordinary skill in the art. Yet other suitable diluents include waxes, sugars (e.g. lactose) and sugar alcohols such as mannitol and sorbitol, acrylate polymers and copolymers, as well as pectin, dextrin and gelatin.
Other excipients include binders, such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes; disintegrants such as sodium starch glycolate, crospovidone, low- substituted hydroxypropyl cellulose and others; lubricants like magnesium and calcium stearate and sodium stearyl fumarate; flavorings; sweeteners; preservatives; pharmaceutically acceptable dyes and glidants such as silicon dioxide.
INSTRUMENTAL DETAILS: High Performance Liquid Chromatography (HPLC):
The purity was measured by high performance liquid chromatography under the following conditions:
Apparatus: Water's HPLC system having alliance 2695 model pump and 2487 (UV) detector with Empower chromatography software or its equivalent. Chromatographic Parameters:
Column : Hypersil (C-18 column)
Detector : UV at 220nm
Flow rate : 1.0ml / min
Injection volume : 10.0 μL Run time : 50 min
Column temperature : 3O0C
Sample temperature : Ambient
Diluent : Water: Acetonitrile-50:50(% v/v)
Solution A: 2.0 ml TEA dissolved in 1000 ml water and pH = 2.2 adjusted with H3PO4 Solution B: Acetonitrile: Methanol - 50:50(v/v)
X-Rav Powder Diffraction (P-XRD):
The X-Ray powder diffraction was measured by an X-ray powder diffractometer equipped with a Cu-anode (λ=l .54 Angstrom), X-ray source operated at 4OkV, 40 mA and a Ni filter is
used to strip K-beta radiation. Two-theta calibration is performed using an NIST SRM 1976, Corundum Standard. The sample was analyzed using the following instrument parameters: measuring range= 3-45° 2Θ; step width=0.01579°; and measuring time per step=0.11 second.
Infra-Red Spectroscopy (FT-IR):
FT-IR spectroscopy was carried out with a Perkin Elmer Spectrum 100 series spectrometer. For the production of the KBr compacts approximately 2 mg of sample was powdered with 200 mg of KBr. The spectra were recorded in transmission mode ranging from 3800 to 450 cm*1.
Differential Scanning Calorimetry (DSC):
DSC (Differential Scanning Calorimetry) measurements were performed with a Differential
Scanning Calorimeter (Perkin Elmer diamond DSC) at a scan rate of 100C per minute.
Bulk Density method of Analysis
About 10 g of sample was placed in a 25 mL measuring cylinder and measured the volume using the following formula:
Bulk density = Weight of the sample (g) / Volume of the sample (mL)
Tap density method of Analysis
About 10 g of sample was placed in a 25 mL measuring cylinder and measured the initial volume. The measuring cylinder was kept in a Sotax Tapping instrument (USP II) and measured the volume of the sample every 50 tappings until a constant volume is obtained using the following formula: Tap Density = Weight of the sample (g) / constant Volume of the sample after tapping (mL)
The following examples are given for the purpose of illustrating the present disclosure and should not be considered as limitation on the scope or spirit of the disclosure.
EXAMPLES Example 1
Preparation of crystalline Form A of N-ethyl-N-phenyl-l-Z-dihydro^-hydroxy-S-chloro- l-methyl-2-oxoquinoline-3-carboxamide (Laquinimod or Laquinimod acid) N-Ethyl aniline (21.22 gm) was dissolved in methylene chloride (925 ml) at 25-3O0C under nitrogen atmosphere. Dichlorotriphenyl phosphorane (97.25 gm) was added to the solution
followed by l,2-Dichloro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3-carboxylic acid (37 gm) at 25-30°C. The reaction mixture was heated to reflux temperature (40-45°C) and then stirred for 6 hours at reflux. The resulting mass was cooled to 25 -30° C followed by the addition of water (370 ml) and then stirred for 15 minutes. The resulting two layers were separated, the organic layer was washed with water (370 ml) at 25-30°C and then distilled out the methylene chloride under vacuum at 40-45 °C. This was followed by the addition of methylene chloride (37 ml) and ethyl acetate (370 ml) at 40-45 °C, the resulting suspension was heated to 60-650C and then stirred for 15 minutes at the same temperature. The resulting mass was cooled to 25-30°C followed by stirring for 1 hour. The resulting solid was filtered, washed with ethyl acetate (2 x 74 ml) at 25-3O0C and then dried the solid at 50-550C in an air oven for 16 hours to produce 40 gm of crystalline Form A of Laquinimod. (HPLC Purity: 99.32%).
Example 2 Preparation of crystalline Form Al of N-ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5- chloro-l-methyl-2-oxoquinoline-3-carboxamide sodium (Laquinimod sodium)
N-Ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide (35 gm) was suspended in ethanol (140 ml) at 20-250C under stirring followed by the addition of freshly prepared sodium hydroxide solution (4.13 gm of sodium hydroxide in 11 ml of water) at 20-250C and then stirred for 15-30 minutes at 25-300C. The resulting solution was filtered through a hyfiow super cell bed and the bed was washed with ethanol (105 ml) at 25-3O0C. The resulting filtrate was seeded with pure laquinimod sodium (0.175 gm) and then stirred for 4 hours at 25-300C. The resulting mass was cooled to 0-50C followed by stirring for 2 hours at the same temperature. The resulting white colored solid was filtered, washed with chilled ethanol (38 ml) and then dried under vacuum at 60-650C to yield 28 gm of laquinimod sodium in crystalline Form Al (HPLC Purity: 99.9%; Bulk density: 0.333 g/ml; Tapped density: 0.476 g/ml; and Particle size distribution: d(0.9) = 26.3 microns).
Example 3 Preparation of crystalline Form A2 of N-ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5- chloro-l-methyl-2-oxoquinoline-3-carboxamide sodium (Laquinimod sodium)
N-Ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide (18 gm) and ethanol (180 ml) were stirred at 25-300C for 15 minutes followed by the addition of 40% sodium hydroxide solution (5.6 ml) at 25-300C in 10 minutes. The resulted clear
solution was stirred at 25-30°C for 20 hours. The precipitated white colored solid was filtered, washed with ethanol (20ml) and then dried at 55-6O0C to a constant weight to yield 13 gm of laquinimod sodium in crystalline Form A2.
Example 4
Preparation of crystalline Form A2 of N-ethyl-N-phenyl-l,2-dihydro-4-b.ydroxy-5- chloro-l-methyl-2-oxoquinoline-3-carboxamide sodium (Laquinimod sodium)
N-Ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide (15 gm) was suspended in isopropyl alcohol (100 ml) at 25-30°C under stirring followed by the addition of freshly prepared sodium hydroxide solution (1.4 gm of sodium hydroxide in 3.5 ml of water) at 20-25°C and then stirred for 15-30 minutes at 25-30°C. The resulting solution was filtered through a hyflow supercell bed and the bed was washed with isopropyl alcohol (50 ml) at 25-3O0C. The resulting filtrate was stirred for 20 hours at 25-3O0C. The resulting white colored solid was filtered, washed with chilled isopropyl alcohol (20 ml) and then dried in air oven at 60-650C to yield 9 gm of laquinimod sodium in crystalline Form A2 (HPLC Purity. 99.8%).
Example 5
Preparation of crystalline Form A3 of N-ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5- chloro-l-methyl-2-oxoquinoline-3-carboxamide sodium (Laquinimod sodium)
Laquinimod sodium (1.5 gm) was dissolved in methanol (10 ml) at 25-3O0C and stirred for 30 minutes. The resulting clear solution was filtered through a hyflow bed and the filtrate was added slowly to diisopropyl ether (500 ml) in 15 minutes at 25-3O0C. The resulting mass was stirred for 24 hours at 25-300C. The separated white colored solid was filtered, washed with diisopropyl ether (20 ml) and then dried at 55-600C to produce 1.3 gm of laquinimod sodium in crystalline Form A3.
Example 6
Preparation of crystalline Form A4 of N-ethyl-N-phenyI-l,2-dihydro-4-hydroxy-5- chloro-l-methyI-2-oxoquinoline-3-carboxamide sodium (Laquinimod sodium)
Laquinimod sodium (2 gm) was dissolved in acetone (10 ml) at 55-60°C and then stirred for 30 minutes. The resulted clear solution was cooled to 25-300C in 30 minutes and the resulting mass was then stirred for 1 hour at 25-300C. The separated solid was filtered and then dried at 53°C to a constant weight to produce 1.1 gm laquinimod sodium in crystalline Form A4.
Example 7 Preparation of Amorphous form of Laquinimod Sodium
Laquinimod sodium (1.5 gm) was dissolved in methanol (10 ml) and stirred for 30 minutes at 25-30°C. The resulted clear solution was filtered through hyflow bed. Methanol was distilled off under vacuum using rotary evaporator at 50-550C to afford 1.2 gm of amorphous laquinimod sodium.
Example 8 Stability of Laquinimod sodium Crystalline Form Al Laquinimod sodium crystalline Form Al was prepared according to the process exemplified in Example 2 and was packed in a self-sealing low-density polyethylene (LDPE) bag. The material was stored for 6 months at a relative humidity of about 60±5% at room temperature (at 25±2°C) and checked for polymorphic stability.
The material was found to retain its polymorphic form after three months of holding, as indicated by maintenance of the original P-XRD pattern.
Example 9 Stability of Laquinimod sodium Crystalline Form Al
Laquinimod sodium crystalline Form Al was prepared according to the process exemplified in Example 2 and was packed in a self-sealing low-density polyethylene (LDPE) bag. The material was stored for 3 months at a relative humidity of about 75±5% at a temperature of about 40±2°C and checked for polymorphic stability.
The material was found to retain its polymorphic form after three months of holding, as indicated by maintenance of the original P-XRD pattern.
Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
The term "crystalline polymorph" refers to a crystal modification that can be characterized by analytical methods such as X-ray powder diffraction, IR-spectroscopy, differential scanning calorimetry (DSC) or by its melting point.
The term "stable crystalline form" refers to stability of the crystalline form under the standard temperature and humidity conditions of testing of pharmaceutical products, wherein the stability is indicated by preservation of the original polymorphic form.
The term "amorphous" means a solid without long-range crystalline order. Amorphous form of laquinimod sodium specifically contains less than about 10% crystalline forms of laquinimod sodium, more specifically less than 5% crystalline forms of laquinimod sodium, and still more specifically is essentially free of crystalline forms of laquinimod sodium. "Essentially free of crystalline forms of laquinimod sodium" means that no crystalline polymorph forms of laquinimod sodium can be detected within the limits of a powder X-ray diffractometer.
The term "pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and includes that which is acceptable for veterinary use and/or human pharmaceutical use.
The term "pharmaceutical composition" is intended to encompass a drug product including the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions encompass any composition made by admixing the active ingredient, active ingredient dispersion or composite, additional active ingredient(s), and pharmaceutically acceptable excipients.
The term "therapeutically effective amount" as used herein means the amount of a compound that, when administered to a mammal for treating a state, disorder or condition, is sufficient to effect such treatment. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the mammal to be treated.
The term "delivering" as used herein means providing a therapeutically effective amount of an active ingredient to a particular location within a host causing a therapeutically effective blood concentration of the active ingredient at the particular location. This can be accomplished, e.g., by topical, local or by systemic administration of the active ingredient to the host.
The term "buffering agent" as used herein is intended to mean a compound used to resist a change in pH upon dilution or addition of acid of alkali. Such compounds include, by way of example and without limitation, potassium metaphosphate, potassium phosphate, monobasic sodium acetate and sodium citrate anhydrous and dehydrate and other such material known to those of ordinary skill in the art.
The term "sweetening agent" as used herein is intended to mean a compound used to impart sweetness to a formulation. Such compounds include, by way of example and without
limitation, aspartame, dextrose, glycerin, mannitol, saccharin sodium, sorbitol, sucrose, fructose and other such materials known to those of ordinary skill in the art.
The term "binders" as used herein is intended to mean substances used to cause adhesion of powder particles in granulations. Such compounds include, by way of example and without limitation, acacia, alginic acid, tragacanth, carboxymethylcellulose sodium, polyvinylpyrrolidone, compressible sugar (e.g., NuTab), ethylcellulose, gelatin, liquid glucose, methylcellulose, pregelatinized starch, starch, polyethylene glycol, guar gum, polysaccharide, bentonites, sugars, invert sugars, poloxamers (PLURONIQ™) F68, PLURONICC™) F 127), collagen, albumin, celluloses in non-aqueous solvents, polypropylene glycol, polyoxyethylene-polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, polyethylene oxide, microcrystalline cellulose, combinations thereof and other material known to those of ordinary skill in the art.
The term "diluent" or "filler" as used herein is intended to mean inert substances used as fillers to create the desired bulk, flow properties, and compression characteristics in the preparation of solid dosage formulations. Such compounds include, by way of example and without limitation, dibasic calcium phosphate, kaolin, sucrose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, starch, combinations thereof and other such materials known to those of ordinary skill in the art.
The term "glidant" as used herein is intended to mean agents used in solid dosage formulations to improve flow-properties during tablet compression and to produce an anti- caking effect. Such compounds include, by way of example and without limitation, colloidal silica, calcium silicate, magnesium silicate, silicon hydrogel, cornstarch, talc, combinations thereof and other such materials known to those of ordinary skill in the art.
The term "lubricant" as used herein is intended to mean substances used in solid dosage formulations to reduce friction during compression of the solid dosage. Such compounds include, by way of example and without limitation, calcium stearate, magnesium stearate, mineral oil, stearic acid, zinc stearate, combinations thereof and other such materials known to those of ordinary skill in the art.
The term "disintegrant" as used herein is intended to mean a compound used in solid dosage formulations to promote the disruption of the solid mass into smaller particles which are more readily dispersed or dissolved. Exemplary disintegrants include, by way of example and without limitation, starches such as corn starch, potato starch, pregelatinized, sweeteners, clays, such as bentonite, microcrystalline cellulose (e.g., Avicel(™)), carsium (e.g., Amberlite(™)), alginates, sodium starch glycolate, gums such as agar, guar, locust bean,
karaya, pectin, tragacanth, combinations thereof and other such materials known to those of ordinary skill in the art.
The term "wetting agent" as used herein is intended to mean a compound used to aid in attaining intimate contact between solid particles and liquids. Exemplary wetting agents include, by way of example and without limitation, gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), poly oxy ethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, (e.g., TWEEN(™)s), polyethylene glycols, polyoxyethylene stearates colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxyl propylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, and polyvinylpyrrolidone (PVP). Tyloxapol (a nonionic liquid polymer of the alkyl aryl polyether alcohol type) is another useful wetting agent, combinations thereof and other such materials known to those of ordinary skill in the art.
The term "micronization" used herein means a process or method by which the size of a population of particles is reduced. As used herein, the term "micron" or "μm" refers to "micrometer" which is 1 x 10'6 meter.
As used herein, "crystalline particles" means any combination of single crystals, aggregates and agglomerates.
As used herein, "Particle Size Distribution (P.S.D)" means the cumulative volume size distribution of equivalent spherical diameters as determined by laser diffraction in Malvern Master Sizer 2000 equipment or its equivalent.
As used herein, Dx means that X percent of the particles have a diameter less than a specified diameter D. Thus, a Dg0 or d(0.9) of less than 300 microns means that 90 volume- percent of the particles in a composition have a diameter less than 300 microns. By "substantially pure" is meant having purity greater than about 98%, specifically greater than about 99%, and more specifically greater than about 99.9% measured by HPLC.
The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be
construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The term wt% refers to percent by weight. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
1. Laquinimod sodium as being greater than 98% pure: a) in a crystalline Form Al ; b) in a crystalline Form A3 ; c) in a crystalline Form A4; or d) in an amorphous form; wherein: e) the crystalline Form Al has at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 4; ii) a powder X-ray diffraction pattern having peaks at about 9.1, 10.7 and 11.2 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.25, 9.72,
10.03, 13.08, 13.91, 14.57, 14.99, 15.69, 16.12, 16.75, 17.57, 18.15, 19.16, 19.87,
20.44, 21.24, 21.68, 21.88, 22.98, 23.79, 24.63 and 25.63 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 5; v) an IR spectrum having absorption bands at about 3377, 3062, 2972, 2933, 1611,
1585, 1528, 1495, 1414, 1377, 1347, 1325, 1255, 1220, 1178, 1098, 811 and 697
± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 6; f) the crystalline Form A3 has at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 10; ii) a powder X-ray diffraction pattern having peaks at about 6.44, 6.65, 7.72 and 8.77
± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 9.31, 9.60,
10.71, 11.14, 11.66, 13.25, 14.61, 15.32, 17.62, 17.98, 18.54, 19.21, 21.38, 22.11,
22.59, 23.43, 23.99, 25.04, 25.44 and 27.86 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 11 ; v) an IR spectrum having absorption bands at about 3368, 2970, 2936, 1615, 1583,
1526, 1495, 1412, 1377, 1344, 1326, 1253, 1218, 1177, 1097, 813 and 699 ± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 12; g) the crystalline Form A4 has at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 13;
ii) a powder X-ray diffraction pattern having peaks at about 6.09, 7.46 and 10.42 ±
0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.82, 8.47,
10.12, 14.15, 16.10, 18.95, 22.66, 23.50, 25.84, 26.13, 28.24, 29.07, 29.81, 31.62 and 33.94 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 14; v) an IR spectrum having absorption bands at about 3413, 2974, 2935, 1612, 1584,
1524, 1495, 1413, 1377, 1346, 1327, 1253, 1219, 1 177, 1097, 811 and 698 ± 2 cm'1; and vi) a DSC thermogram substantially in accordance with Figure 15; h) the amorphous form has at least one, or more, of the following properties: i) a powder XRD pattern substantially in accordance with Figure 16; ii) an IR spectrum substantially in accordance with Figure 17; and iii) an IR spectrum having absorption bands at about 3401, 2973, 2936, 1612, 1584,
1525, 1494, 1412, 1377, 1345, 1327, 1253, 1219, 1177, 1097, 813 and 698 ± 2 cm"1.
2. A crystalline Form Al of laquinimod sodium characterized by at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 4; ii) a powder X-ray diffraction pattern having peaks at about 9.1, 10.7 and 1 1.2 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.25, 9.72, 10.03,
13.08, 13.91, 14.57, 14.99, 15.69, 16.12, 16.75, 17.57, 18.15, 19.16, 19.87, 20.44,
21.24, 21.68, 21.88, 22.98, 23.79, 24.63 and 25.63 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 5; v) an IR spectrum having absorption bands at about 3377, 3062, 2972, 2933, 1611, 1585,
1528, 1495, 1414, 1377, 1347, 1325, 1255, 1220, 1178, 1098, 811 and 697 ± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 6.
3. The laquinimod sodium crystalline Form Al of claim 2, having a bulk density of at least about 0.30 g/ml, and a tapped density of at least about 0.40 g/ml.
4. The laquinimod sodium crystalline Form Al of claim 3, having a bulk density of about 0.30 g/ml to about 0.35 g/ml, and a tapped density of about 0.45 g/ml to about 0.50 g/ml.
5. A process for the preparation of laquinimod sodium crystalline Form Al of claim 2, comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) stirring the solution at about 15-300C to form a first reaction mass; e) cooling the first reaction mass at below about 100C to form a second reaction mass; and f) recovering the crystalline Form Al of laquinimod sodium from the second reaction mass.
6. The process of claim 5, wherein the alcohol solvent used in step-(a) is a Ci to C6 straight or branched chain alcohol solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof.
7. The process of claim 6, wherein the alcohol solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol and mixtures thereof.
8. The process of claim 7, wherein the alcohol solvent is ethanol.
9. The process of claim 5, wherein the solution in step-(a) is provided by dissolving laquinimod sodium in the alcoholic solvent at a temperature of below about reflux temperature of the solvent used.
10. The process of claim 9, wherein the dissolution is carried out at a temperature of about 2O0C to about 8O0C.
11. The process of claim 5, wherein the solution in step-(a) is prepared by providing a suspension of laquinimod in an alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution.
12. The process of claim 11, wherein the suspension of laquinimod is provided by suspending the laquinimod in the alcoholic solvent under stirring at a temperature of below about reflux temperature of the solvent.
13. The process of claim 11, wherein the suspension of laquinimod is provided by reacting l,2-dichloro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3-carboxylic acid with N- ethyl aniline in the presence of a suitable coupling agent, optionally in the presence of a base, in a suitable solvent under suitable conditions to produce a reaction mass containing crude laquinimod acid; subjecting the reaction mass to washings, extractions or evaporations; and suspending the resulting laquinimod in the alcoholic solvent under stirring at a temperature of below about reflux temperature of the solvent.
14. The process of claim 5, wherein the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment.
15. The process of claim 5, wherein the solution in step-(d) is stirred for at least 1 hour at a temperature of about 2O0C to about 30°C.
16. The process of claim 15, wherein the solution is stirred for about 2 hours to about 6 hours.
17. The process of claim 5, wherein the solution in step-(e) is cooled under stirring at a temperature of about 0 to about 10°C for at least 15 minutes.
18. The process of claim 17, wherein the solution is stirred at a temperature of about 0 to about 50C for about 30 minutes to about 4 hours.
19. The process of claim 5, wherein recovering in step-(f) is carried out by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
20. The process of claim 5, wherein the substantially pure laquinimod sodium crystalline Form Al obtained in step-(f) is further dried under vacuum or at atmospheric pressure, at a temperature of about 350C to about 7O0C.
21. A crystalline Form A3 of laquinimod sodium characterized by at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 10; ii) a powder X-ray diffraction pattern having peaks at about 6.44, 6.65, 7.72 and 8.77 ±
0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 9.31, 9.60, 10.71,
11.14, 11.66, 13.25, 14.61, 15.32, 17.62, 17.98, 18.54, 19.21, 21.38, 22.11, 22.59,
23.43, 23.99, 25.04, 25.44 and 27.86 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 11 ; v) an IR spectrum having absorption bands at about 3368, 2970, 2936, 1615, 1583, 1526,
1495, 1412, 1377, 1344, 1326, 1253, 1218, 1177, 1097, 813 and 699 ± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 12.
22. A process for the preparation of laquinimod sodium crystalline Form A3 of claim 21, comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) admixing the solution with an anti-solvent; and
e) recovering the crystalline Form A3 of laquinimod sodium from the reaction mass obtained in step-(d).
23. The process of claim 22, wherein the alcohol solvent used in step-(a) is a C1 to C6 straight or branched chain alcohol solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof.
24. The process of claim 23, wherein the alcohol solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol and mixtures thereof.
25. The process of claim 24, wherein the alcohol solvent is ethanol.
26. The process of claim 22, wherein the solution in step-(a) is provided by dissolving laquinimod sodium in the alcoholic solvent at a temperature of below about reflux temperature of the solvent.
27. The process of claim 26, wherein the dissolution is carried out at about 2O0C to about 8O0C.
28. The process of claim 22, wherein the solution in step-(a) is prepared by providing a suspension of laquinimod in an alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution.
29. The process of claim 22, wherein the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment.
30. The process of claim 22, wherein the anti-solvent used in step-(d) is selected from the group consisting of an ether, a hydrocarbon, and mixtures thereof.
31. The process of claim 30, wherein the ether solvent is selected from the group consisting of diisopropyl ether, diethyl ether, tetrahydrofuran, dioxane, and mixtures thereof; and wherein the hydrocarbon solvent is selected from the group consisting of n-pentane, n- hexane and n-heptane and their isomers, cyclohexane, toluene, xylene, and mixtures thereof.
32. The process of claim 30, wherein the anti-solvent is diisopropyl ether.
33. The process of claim 22, wherein the admixing in step-(d) is accomplished by adding the solution to the anti-solvent or by adding the anti-solvent to the solution.
34. The process of claim 33, wherein the addition is carried out at a temperature of below 500C for at least 15 minutes.
35. The process of claim 34, wherein the addition is carried out at a temperature of about 150C to about 350C for about 20 minutes to about 2 hours.
36. The process of claim 22, wherein recovering in step-(e) is carried out by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
37. The process of claim 22, wherein the substantially pure laquinimod sodium crystalline Form A3 obtained in step-(e) is further dried under vacuum or at atmospheric pressure, at a temperature of about 350C to about 7O0C.
38. A crystalline Form A4 of laquinimod sodium characterized by at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 13; ii) a powder X-ray diffraction pattern having peaks at about 6.09, 7.46 and 10.42 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.82, 8.47, 10.12,
14.15, 16.10, 18.95, 22.66, 23.50, 25.84, 26.13, 28.24, 29.07, 29.81, 31.62 and 33.94
± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 14; v) an IR spectrum having absorption bands at about 3413, 2974, 2935, 1612, 1584, 1524,
1495, 1413, 1377, 1346, 1327, 1253, 1219, 1177, 1097, 811 and 698 ± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 15.
39. A process for the preparation of laquinimod sodium crystalline Form A4 of claim 38, comprising: a) providing a solution of laquinimod sodium in a ketone solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; and d) isolating crystalline Form A4 of laquinimod sodium from the solution.
40. The process of claim 39, wherein the ketone solvent used in step-(a) is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert- butyl ketone, and mixtures thereof.
41. The process of claim 40, wherein the ketone solvent is acetone.
42. The process of claim 39, wherein the solution in step-(a) is provided by dissolving laquinimod sodium in the ketone solvent at a temperature of below about reflux temperature of the solvent.
43. The process of claim 42, wherein the dissolution is carried out at a temperature of about 4O0C to about 8O0C.
44. The process of claim 39, wherein the solution in step-(a) is prepared by providing a suspension of laquinimod in a ketone solvent followed by combining the suspension with sodium hydroxide base and then heating the resulting mass to form a clear solution.
45. The process of claim 39, wherein the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment.
46. The process of claim 39, wherein the isolation of laquinimod sodium crystalline Form A4 in step-(d) is carried out by cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, or a combination thereof.
47. The process of claim 46, wherein the isolation is carried out by cooling the solution at a temperature of below 3O0C.
48. The process of claim 47, wherein the isolation is carried out at about O0C to about 250C.
49. The process of claim 39, wherein the solid obtained in step-(d) is recovered by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
50. The process of claim 39, wherein the substantially pure laquinimod sodium crystalline Form A4 obtained in step-(d) is further dried under vacuum or at atmospheric pressure, at a temperature of about 350C to about 7O0C.
51. Amorphous form of laquinimod sodium.
52. The Amorphous form of laquinimod sodium of claim 51, characterized by at least one, or more, of the following properties: i) a powder XRD pattern substantially in accordance with Figure 16; ii) an IR spectrum substantially in accordance with Figure 17; and iii) an IR spectrum having absorption bands at about 3401, 2973, 2936, 1612, 1584, 1525, 1494, 1412, 1377, 1345, 1327, 1253, 1219, 1177, 1097, 813 and 698 ± 2 cm'1.
53. A process for the preparation of amorphous laquinimod sodium of claim 51, comprising: a) providing a solution of laquinimod sodium in a solvent selected from the group consisting of an alcohol, a ketone, and mixtures thereof; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; and d) substantially removing the solvent from the solution to provide amorphous form of laquinimod sodium.
54. The process of claim 53, wherein the alcohol solvent used in step-(a) is a Cj to C6 straight or branched chain alcohol solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof; and
wherein the ketone solvent is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, and mixtures thereof.
55. The process of claim 54, wherein the alcohol solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol and mixtures thereof; and wherein the ketone solvent is acetone.
56. The process of claim 53, wherein the solution in step-(a) is provided by dissolving laquinimod sodium in the solvent at a temperature of below about reflux temperature of the solvent used.
57. The process of claim 56, wherein the dissolution is carried out at a temperature of about 200C to about 8O0C.
58. The process of claim 53, wherein the solution in step-(a) is prepared by providing a suspension of laquinimod in a solvent selected from the group consisting of an alcohol, a ketone, and mixtures thereof; combining the suspension with aqueous sodium hydroxide solution and optionally heating the resulting mass until to form a clear solution.
59. The process of claim 53, wherein the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment.
60. The process of claim 53, wherein the removal of the solvent in step-(d) is accomplished by distillation or complete evaporation of the solvent, spray drying, vacuum drying, lyophilization or freeze drying, agitated thin-film (ATFD) drying, or a combination thereof.
61. The process of claim 53, wherein a substantially pure amorphous form of laquinimod sodium obtained in step-(d) is further dried under vacuum or at atmospheric pressure, at a temperature of about 350C to about 7O0C.
62. An improved process for the preparation of crystalline Form A2 of laquinimod sodium, comprising: a) providing a solution of laquinimod sodium in an alcoholic solvent; b) optionally, filtering the solvent solution to remove any extraneous matter; c) optionally, seeding the solution; d) stirring the solution at a temperature of about 20-300C for at least 1 hour to produce a reaction mass; and e) recovering the crystalline Form A2 of laquinimod sodium from the reaction mass obtained in step-(d).
63. The process of claim 62, wherein the laquinimod sodium crystalline Form A2 is characterized by at least one, or more, of the following properties:
i) a powder X-ray diffraction pattern substantially in accordance with Figure 7; ii) a powder X-ray diffraction pattern having peaks at about 8.36, 25.10 and 29.35 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 7.22, 9.68, 10.00,
11.79, 13.37, 13.78, 14.08, 14.31, 14.62, 15.02, 15.73, 16.14, 16.74, 17.82, 18.20,
18.90, 20.07, 22.09, 23.17 and 24.08 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 8; v) an IR spectrum having absorption bands at about 3301, 2971, 2935, 1613, 1585, 1526,
1495, 1414, 1378, 1347, 1328, 1253, 1220, 1178, 1098, 811 and 700 ± 2 cm"1; and vi) a DSC thermogram substantially in accordance with Figure 9.
64. The process of claim 62, wherein the alcohol solvent used in step-(a) is a Ci to C6 straight or branched chain alcohol solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, butanol, amyl alcohol, hexanol, and mixtures thereof.
65. The process of claim 64, wherein the alcohol solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol and mixtures thereof.
66. The process of claim 62, wherein the solution in step-(a) is provided by dissolving laquinimod sodium in the alcoholic solvent at a temperature of below about reflux temperature of the solvent used.
67. The process of claim 66, wherein the dissolution is carried out at a temperature of about 2O0C to about 8O0C.
68. The process of claim 62, wherein the solution in step-(a) is prepared by providing a suspension of laquinimod in an alcoholic solvent followed by combining the suspension with aqueous sodium hydroxide solution to form a clear solution.
69. The process of claim 62, wherein the solution obtained in step-(a) is optionally subjected to carbon treatment or silica get treatment.
70. The process of claim 62, wherein the solution in step-(d) is stirred at a temperature of about 25°C to about 30°C for about 6 hours to about 30 hours.
71. The process of claim 62, wherein recovering in step-(e) is carried out by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
72. The process of claim 62, wherein the substantially pure laquinimod sodium crystalline Form A2 obtained in step-(e) is further dried under vacuum or at atmospheric pressure, at a temperature of about 350C to about 700C.
73. A crystalline Form A of laquinimod acid characterized by at least one, or more, of the following properties: i) a powder X-ray diffraction pattern substantially in accordance with Figure 1 ; ii) a powder X-ray diffraction pattern having peaks at about 7.15, 12.58, 14.84, 25.09 and 26.38 ± 0.2 degrees 2-theta; iii) a powder X-ray diffraction pattern having additional peaks at about 6.19, 8.78, 14.04,
14.37, 15.36, 16.20, 18.48, 18.81, 20.44, 20.73, 21.71, 23.21, 23.50, 23.76, 28.96 and
31.08 ± 0.2 degrees 2-theta; iv) an IR spectrum substantially in accordance with Figure 2; v) an IR spectrum having absorption bands at about 3081, 2976, 1647, 1617, 1586, 1562,
1496, 1378, 1327, 1303, 1237, 1197, 812 and 701 ± 2 cm'1; and vi) a DSC thermogram having an endotherm peak at about 240°C substantially as depicted in Figure 3.
74. A process for the preparation of laquinimod crystalline Form A of claim 73, comprising: a) providing a suspension of N-ethyl-N-phenyl-l,2-dihydro-4-hydroxy-5-chloro-l- methyl-2-oxoquinoline-3-carboxamide (laquinimod or laquinimod acid) in a solvent medium comprising an ester solvent and a halogenated hydrocarbon solvent; b) optionally, cooling the suspension obtained in step-(a); and c) recovering crystalline Form A of laquinimod from the suspension.
75. The process of claim 74, wherein the halogenated hydrocarbon solvent is selected from the group consisting of methylene chloride, 1,2-dichloroethane, chloroform, carbon tetrachloride, and mixtures thereof; and wherein the ester solvent is selected from the group consisting of methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n- butyl acetate, isobutyl acetate, tert-butyl acetate, ethyl formate, and mixtures thereof.
76. The process of claim 75, wherein the halogenated hydrocarbon solvent is methylene chloride and wherein the ester solvent is ethyl acetate.
77. The process of claim 74, wherein the suspension in step-(a) is provided by suspending laquinimod in the solvent medium under stirring at below reflux temperature of the solvent medium used.
78. The process of claim 74, wherein the suspension in step-(a) is prepared by reacting 1,2- dichloro-4-hydroxy-5-chloro-l-methyl-2-oxo-quinoline-3-carboxylic acid with N-ethyl aniline in the presence of a suitable coupling agent, optionally in the presence of a base, in a suitable solvent under suitable conditions to produce a reaction mass containing crude laquinimod acid; subjecting the reaction mass to washings, extractions,
evaporations, or combination thereof; and suspending the resulting crude laquinimod in the solvent medium under stirring at below reflux temperature of the solvent medium used.
79. The process of claim 74, wherein the suspension in step-(a) is prepared by treating a pharmaceutically acceptable salt of laquinimod with an acid to produce laquinimod acid and suspending the laquinimod acid in the solvent medium at below reflux temperature of the solvent medium.
80. The process of any one of claims 77-79, wherein the suspension is stirred at a temperature of about 3O0C to about 1000C for at least 15 minutes.
81. The process of claim 80, wherein the suspension is stirred at about 4O0C to about 8O0C for about 30 minutes to about 5 hours.
82. The process of claim 74, wherein the suspension in step-(b) is cooled at a temperature of below 3O0C under stirring for at least 15 minutes.
83. The process of claim 82, wherein the suspension is cooled at a temperature of about 1O0C to about 3O0C for about 30 minutes to 2 hours.
84. The process of claim 74, wherein recovering in step-(c) is carried out by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
85. The process of claim 74, wherein the substantially pure laquinimod crystalline Form A obtained in step-(c) is further dried under vacuum or at atmospheric pressure, at a temperature of about 350C to about 700C.
86. A pharmaceutical composition comprising a therapeutically effective amount of laquinimod crystalline Form A and one or more pharmaceutically acceptable excipients.
87. A pharmaceutical composition comprising a therapeutically effective amount of any one or a mixture of the laquinimod sodium solid state forms (Form Al, Form A3, Form A4 and amorphous form), and one or more pharmaceutically acceptable excipients.
88. A process for preparing the pharmaceutical composition of claim 87, comprising combining the laquinimod sodium solid state form of any one of claims 2, 21, 38 and 51, with one or more pharmaceutically acceptable excipients.
89. A pharmaceutical composition comprising a therapeutically effective amount of laquinimod sodium crystalline Form Al of claim 2 and one or more pharmaceutically acceptable excipients.
90. A pharmaceutical composition comprising a therapeutically effective amount of laquinimod sodium crystalline Form A3 of claim 21 and one or more pharmaceutically acceptable excipients.
91. A pharmaceutical composition comprising a therapeutically effective amount of laquinimod sodium crystalline Form A4 of claim 38 and one or more pharmaceutically acceptable excipients.
92. A pharmaceutical composition comprising a therapeutically effective amount of amorphous laquinimod sodium of claim 51 and one or more pharmaceutically acceptable excipients.
93. The pharmaceutical composition of any one of claims 86, 87 and 89-92, wherein the pharmaceutical composition is a solid dosage form, an oral suspension, a liquid, a powder, an elixir, an aerosol, syrups or an injectable solution.
94. The pharmaceutical composition of any one of claims 87 and 89-92, wherein the solid state form of laquinimod sodium has a D90 particle size of less than or equal to about 500 microns.
95. The pharmaceutical composition of claim 94, wherein the solid state form of laquinimod sodium has a D90 particle size of less than or equal to about 300 microns; less than or equal to about 100 microns; less than or equal to about 60 microns; or less than or equal to about 15 microns.
96. A method for treating a patient suffering from diseases caused by multiple sclerosis, insulin-dependent diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis, asthma, atherosclerosis, stroke and Alzheimer's disease; comprising administering any one or a mixture of the solid state forms of laquinimod sodium (Form Al, Form A3, Form A4 and amorphous form), or a pharmaceutical composition that comprises any one or a mixture of the solid state forms of laquinimod sodium along with pharmaceutically acceptable excipients.
97. Use of the laquinimod crystalline Form A of claim 73 in the process for preparation of laquinimod sodium.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/001,715 US8354428B2 (en) | 2008-07-01 | 2009-06-30 | Solid state forms of laquinimod and its sodium salt |
EP09772917A EP2318371A2 (en) | 2008-07-01 | 2009-06-30 | Novel solid state forms of laquinimod and its sodium salt |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1602CH2008 | 2008-07-01 | ||
IN1602/CHE/2008 | 2008-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010001257A2 true WO2010001257A2 (en) | 2010-01-07 |
WO2010001257A3 WO2010001257A3 (en) | 2011-03-31 |
Family
ID=41466382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/006560 WO2010001257A2 (en) | 2008-07-01 | 2009-06-30 | Novel solid state forms of laquinimod and its sodium salt |
Country Status (3)
Country | Link |
---|---|
US (1) | US8354428B2 (en) |
EP (1) | EP2318371A2 (en) |
WO (1) | WO2010001257A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109526A1 (en) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
JP2013534536A (en) * | 2010-07-09 | 2013-09-05 | テバ ファーマシューティカル インダストリーズ リミティド | 5-Chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses thereof |
US20130345257A1 (en) * | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
US8865742B2 (en) | 2010-11-28 | 2014-10-21 | Mapi Pharma Ltd. | Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium |
CN104955522A (en) * | 2012-11-07 | 2015-09-30 | 梯瓦制药工业有限公司 | Amine salts of laquinimod |
EP2882495A4 (en) * | 2012-08-13 | 2016-04-06 | Teva Pharma | Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders |
US9662322B2 (en) | 2014-04-29 | 2017-05-30 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
EP3116554A4 (en) * | 2014-03-14 | 2017-08-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of laquinimod by oral patches |
US20210386731A1 (en) * | 2012-06-05 | 2021-12-16 | Active Biotech Ab | Treatment of ocular inflammatory diseases using laquinimod |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53666B1 (en) | 2005-10-19 | 2015-04-30 | Teva Pharmaceutical Industries Ltd | Crystals of laquinimod sodium, and process for the manufacture thereof |
US8584956B2 (en) * | 2009-10-13 | 2013-11-19 | Square, Inc. | Systems and methods for passive identification circuitry |
US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CN105960238A (en) * | 2013-11-15 | 2016-09-21 | 梯瓦制药工业有限公司 | Treatment of glaucoma using laquinimod |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
WO2005074899A2 (en) * | 2004-02-06 | 2005-08-18 | Active Biotech Ab | New compositions containing quinoline compounds |
WO2007047863A2 (en) * | 2005-10-19 | 2007-04-26 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
-
2009
- 2009-06-30 WO PCT/IB2009/006560 patent/WO2010001257A2/en active Application Filing
- 2009-06-30 EP EP09772917A patent/EP2318371A2/en not_active Withdrawn
- 2009-06-30 US US13/001,715 patent/US8354428B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
WO2005074899A2 (en) * | 2004-02-06 | 2005-08-18 | Active Biotech Ab | New compositions containing quinoline compounds |
WO2007047863A2 (en) * | 2005-10-19 | 2007-04-26 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
Non-Patent Citations (2)
Title |
---|
JANSSON, K. ET AL: "Synthesis and Reactivity of Laquinimod, a Quinoline-3-carboxamide: Intramolecular Transfer of the ENOL Proton to a Nitrogen Atom as a Plausible Mechanism for Ketene Formation" JOURNAL OF ORGANIC CHEMISTRY, vol. 71, no. 4, 21 January 2006 (2006-01-21), pages 1658-1667, XP002568742 * |
JÖNSSON, S. ET AL: "Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecar boxamides for Treatment of Autoimmune Disorders: Structure-Activity Relationship" JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 8, 16 March 2004 (2004-03-16), pages 2075-2088, XP002568743 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109526A1 (en) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
EP2542078A1 (en) * | 2010-03-03 | 2013-01-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
JP2013521303A (en) * | 2010-03-03 | 2013-06-10 | テバ ファーマシューティカル インダストリーズ リミティド | Treatment of lupus nephritis with laquinimod |
EP2542078A4 (en) * | 2010-03-03 | 2013-07-10 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
JP2016128464A (en) * | 2010-03-03 | 2016-07-14 | テバ ファーマシューティカル インダストリーズ リミティド | Treatment of lupus nephritis using laquinimod |
US8889661B2 (en) | 2010-03-03 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of lupus nephritis using laquinimod |
JP2013534536A (en) * | 2010-07-09 | 2013-09-05 | テバ ファーマシューティカル インダストリーズ リミティド | 5-Chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses thereof |
JP2016053049A (en) * | 2010-07-09 | 2016-04-14 | テバ ファーマシューティカル インダストリーズ リミティド | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts thereof and uses thereof |
US9102592B2 (en) | 2010-11-28 | 2015-08-11 | Mapi Pharma Ltd. | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium |
US8865742B2 (en) | 2010-11-28 | 2014-10-21 | Mapi Pharma Ltd. | Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium |
US20210386731A1 (en) * | 2012-06-05 | 2021-12-16 | Active Biotech Ab | Treatment of ocular inflammatory diseases using laquinimod |
US11654140B2 (en) | 2012-06-05 | 2023-05-23 | Active Biotech Ab | Treatment of ocular inflammatory diseases using laquinimod |
US20130345257A1 (en) * | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
EP2882495A4 (en) * | 2012-08-13 | 2016-04-06 | Teva Pharma | Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders |
CN104955522A (en) * | 2012-11-07 | 2015-09-30 | 梯瓦制药工业有限公司 | Amine salts of laquinimod |
EP2916915A4 (en) * | 2012-11-07 | 2016-06-22 | Teva Pharma | Amine salts of laquinimod |
EP3116554A4 (en) * | 2014-03-14 | 2017-08-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of laquinimod by oral patches |
US9662322B2 (en) | 2014-04-29 | 2017-05-30 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
Also Published As
Publication number | Publication date |
---|---|
EP2318371A2 (en) | 2011-05-11 |
WO2010001257A3 (en) | 2011-03-31 |
US20110171270A1 (en) | 2011-07-14 |
US8354428B2 (en) | 2013-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8354428B2 (en) | Solid state forms of laquinimod and its sodium salt | |
US9512060B2 (en) | Solid state forms of tapentadol salts | |
US20100272815A1 (en) | Amorphous form of tapentadol hydrochloride | |
US20110014291A1 (en) | Novel Polymorphs of Bosentan | |
WO2012004677A1 (en) | Solid state forms of etoricoxib salts | |
US20110117200A1 (en) | Rasagiline mesylate particles and process for the preparation thereof | |
US20110097413A1 (en) | Solid state forms of deferasirox salts and process for the preparation thereof | |
US20110171274A1 (en) | Fesoterodine Substantially Free of Dehydroxy Impurity | |
US20110021547A1 (en) | Substantially Pure and a Stable Crystalline Form of Bosentan | |
US20100297241A1 (en) | Amorphous Fesoterodine Fumarate | |
US20110046231A1 (en) | Solid forms of (±)-o-desmethylvenlafaxine salts | |
US20090061005A1 (en) | Paliperidone Polymorphs | |
US20110014246A1 (en) | Amorphous arformoterol l-(+)-tartrate | |
US20130324554A1 (en) | Amorphous form of vilazodone hydrochloride substantially free of crystalline forms | |
US20120093887A1 (en) | Amorphous varenicline tartrate co-precipitates | |
WO2014016842A1 (en) | Amorphous coprecipitates of rivaroxaban | |
US20100260851A1 (en) | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium | |
US20090246284A1 (en) | O-desmethylvenlafaxine Cocrystals | |
WO2015037010A1 (en) | Preparation of vilazodone hydrochloride crystalline form iv | |
US20120269871A1 (en) | Solid state forms of rasagiline salts | |
US20100204296A1 (en) | Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt | |
WO2010029436A2 (en) | Novel solid state forms of ranolazine salts | |
US20120100188A1 (en) | Solid state forms of paliperidone salts and process for the preparation thereof | |
WO2010038154A2 (en) | Polymorphic forms of rosiglitazone hydrogensulfate and processes for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09772917 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009772917 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13001715 Country of ref document: US |